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Abstract
After a request from the European Commission, EFSA’s Panel on Animal Health and Welfare
summarised the main characteristics of 36 vector-borne diseases (VBDs) in 36 web-based storymaps.
The risk of introduction in the EU through movement of livestock or pets was assessed for each of the
36 VBDs individually, using a semiquantitative Method to INTegrate all relevant RISK aspects
(MINTRISK model), which was further modiﬁed to a European scale into the EFSA-VBD-RISK-model.
Only eight of the 36 VBD-agents had an overall rate of introduction in the EU (being the combination
of the rate of entry, vector transmission and establishment) which was estimated to be above 0.001
introductions per year. These were Crimean-Congo haemorrhagic fever virus, bluetongue virus, West
Nile virus, Schmallenberg virus, Hepatozoon canis, Leishmania infantum, Bunyamwera virus and
Highlands J. virus. For these eight diseases, the annual extent of spread was assessed, assuming the
implementation of available, authorised prevention and control measures in the EU. Further, the
probability of overwintering was assessed, as well as the possible impact of the VBDs on public health,
animal health and farm production. For the other 28 VBD-agents for which the rate of introduction was
estimated to be very low, no further assessments were made. Due to the uncertainty related to some
parameters used for the risk assessment or the instable or unpredictability disease situation in some of
the source regions, it is recommended to update the assessment when new information becomes
available. Since this risk assessment was carried out for large regions in the EU for many VBD-agents,
it should be considered as a ﬁrst screening. If a more detailed risk assessment for a speciﬁc VBD is
wished for on a national or subnational level, the EFSA-VBD-RISK-model is freely available for this
purpose.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
According to a request from the European Commission, EFSA’s Panel on Animal Health and Welfare
(AHAW) was asked to: identify, rank and brieﬂy characterise the vector-borne diseases (VBDs) that
present a risk for the European Union (EU) because of their introduction, re-introduction or further
spread (Term of Reference 1 (TOR 1)); identify and rank possible pathways of introduction and further
spread into the EU and Assess the potential speed of propagation in the EU for each disease identiﬁed
in point 1 (TOR 2); detail the potential health consequences and other impacts to the EU (TOR 3);
assess the risk of each disease becoming endemic in the animal population in the EU (TOR 4); brieﬂy
review the feasibility, availability and effectiveness of the main disease prevention and control
measures (TOR 5).
The risk was assessed separately for four regions in the EU: northern EU (N-EU): Lithuania,
Denmark, Latvia, Ireland, Finland, Estonia, Sweden, United Kingdom); southern EU (S-EU): Spain,
Greece, Malta, Italy, Croatia, Slovenia, Portugal, Cyprus); W-EU (W-EU): Belgium, Netherlands,
Luxembourg, France, Germany, Austria; and eastern EU (E-EU): Hungary, Poland, Czech Republic,
Bulgaria, Slovakia, Romania).
To identify and characterise the VBDs (TOR 1), a set of selection criteria was agreed upon
with the requestor of the mandate, to prioritise the vector-borne disease agents (VBD-agents) for
which the risk assessment had to be carried out. First, the assessment was restricted to pathogens
that are biologically transmitted by arthropod vectors, such as sandﬂies, mosquitoes, ticks or biting
midges. Thus, pathogens that are transmitted by other vectors, such as rodent-borne pathogens or
mechanically transmitted pathogens, were excluded from this risk assessment. Additionally, in the
context of potentially ﬁne-tuning or updating animal health legislation, it was suggested to focus the
risk assessment on exotic pathogens (here deﬁned as the individual pathogen being present in
maximum one EU-region in the EU) affecting the most important livestock and pet species. Exceptions
on this latter selection criterion were bluetongue virus, Schmallenberg virus, African swine fever virus,
West Nile virus, and Leishmania infantum which were also included in the risk assessment on special
request, although they are not considered exotic, as each individually occur in more than one region in
the EU. Diseases that were transmitted by tsetse ﬂies were also excluded as to date there is no
evidence of the presence of these vectors in the EU. Applying these criteria resulted in the
identiﬁcation of 39 pathogens. During the data collection for the risk assessment, another three
disease agents (Semliki forest disease virus, Cocal virus and Ibaraki virus) were removed from the list
of selected diseases, as there was either no evidence found that the disease agents affect livestock or
pet species (Semliki forest disease) or they were considered the same species of other disease agents
already in the list (such as Cocal virus and Ibaraki virus, which were assessed together with vesicular
stomatitis virus and epizootic haemorrhagic disease, respectively). The remaining 36 VBDs were
characterised in 36 web-based storymaps and the risk of introduction was assessed for each
individually.
For the risk assessment and ranking (TOR 2), a Method to INTegrate all relevant RISK aspects
(MINTRISK) developed by de Vos et al. (2016) to assess the risk for VBDs in the Netherlands was
further modiﬁed to a European scale into the EFSA-VBD_RISK model. The tool allowed for a
systematic, semiquantitative risk assessment and was further used for the ranking of the VBDs. The
probability of each step of the risk pathway was calculated choosing from a low, moderate or high
uncertainty level. Data inputs from systematic literature review and expert opinions were used to
obtain the required parameters according to the model. Therefore, the model sampled a value from
different triangular distributions according to the chosen uncertainty levels.
First, the rates of entry, the level of transmission, and the probability of establishment were
calculated separately, and then these three probabilities were combined into an overall rate of
introduction (TOR 2).
According to the model there is a high to very high rate of entry (1 entry per 10 years to 1 entry
per year) of L. infantum, Hepatozoon canis, bluetongue virus, West Nile virus, Bhanja virus Crimean
Congo haemorrhagic fever virus, Schmallenberg virus, Thogoto virus, equine encephalosis virus Palyam
virus and Venezuelan equine encephalitis virus in all four EU regions through movement of livestock or
pets from infected regions in or outside the EU.
In contrast, the rate of entry of Aino virus, bovine ephemeral fever virus, Akabane virus, Kotonkon
virus, Middelburg virus, Wesselbron virus, Nairobi sheep disease virus, epizootic haemorrhagic disease
virus, African horse sickness virus, Getah virus, Japanese encephalitis virus and Rift Valley fever virus
was estimated to be very low (less than 1 entry every 10,000 years).
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The main parameters contributing to the probability of entry were the prevalence of infection in
susceptible hosts in source areas, the numbers of animals moved into the EU and the probability that
the pathogen is still present in the host upon arrival in the EU. Detection of the latter is determined
mainly by the sensitivity of the tests (if testing is carried out) and the infectious period in the hosts.
There was a high uncertainty around the prevalence of some of the VBDs in the source areas and the
frequency of the outbreaks for not-reportable diseases. It should be noted that when the number of
animals imported change due to different trade policies or the prevalences of the VBDs in the source
areas changes, the rate of entry will subsequently change too. It should be noted that the entry
through movement of vectors and free movement of wild animals were not considered in the model.
The expected level of vector transmission of epizootic haemorrhagic disease virus, Palyam virus,
bluetongue virus and equine encephalosis virus was estimated to be high in the four regions of the EU,
with basic reproduction ratio (R0) values between 3 and 10.
Bunyamwera virus, Eastern equine encephalitis virus, Shuni virus, Venezuelan equine encephalitis
virus, Western equine encephalitis virus, Getah virus, Highlands J. virus and Middelburg virus were
estimated to have a low to very low level of transmission everywhere in the EU with R0 values smaller
than 0.3.
For all the other VBD-agents, the level of transmission was expected to be moderate everywhere in
the EU (R0 between 1 and 3), except in W-EU where the level of transmission of Alkhurma
haemorrhagic fever virus, Ehrlichia ruminantium, Nairobi sheep disease virus, Thogoto virus and
Yunnan orbivirus (YUOV) was estimated to be very low. Also, in E-EU, the level of transmission of
Bhanja virus, E. ruminantium, Nairobi sheep disease virus was estimated to be very low, as well as in
S-EU the level of transmission of Alkhurma haemorrhagic fever virus, in N-EU the level of transmission
of L. infantum, Nairobi sheep disease virus and Yunnan orbivirus.
The R0 values were generally associated with a moderate to high uncertainty, due to the high
uncertainty related to one or more of the parameters needed to calculate the ratio, such as the biting
rate, the vector competence or the extrinsic incubation period in the vectors. Additionally, for some of
the VBD pathogens, the distribution of the potential competent vectors in the EU has never been
investigated.
The probability of establishment, being the probability that the pathogen can spread from
vector to host and vice versa given the conditions of introduction (pathway, time and place) of
Akabane virus, bluetongue virus, Crimean-Congo haemorrhagic fever virus, Eastern equine encephalitis
virus, epizootic haemorrhagic disease virus, Schmallenberg virus, West Nile virus, Getah virus and
Japanese encephalitis virus was estimated to be high to very high (with a probability of 0.1 to 1 per
introduction), depending on the region of the EU.
For most of the other diseases, however, the probability of establishment was estimated to be low
to very low (with a probability of less than 0.0001 per introduction). In general, there is a much higher
probability of establishment for animals which are imported for breeding, compared to animals which
are imported for direct slaughter upon arrival.
The proportion of areas with a high vector density could not be calculated for Alkhurma
haemorrhagic fever virus, African swine fever virus, E. ruminantium, H. canis, Palyam virus, Kotonkon
virus, main drain virus, Middelburg virus, Nairobi sheep disease virus, Peruvian horse sickness virus,
Thogoto virus and vesicular stomatitis virus as there is lack of spatial data on the distribution of the
vectors. Therefore, the probability of establishment of these diseases was associated with a high
uncertainty.
According to the model Crimean-Congo haemorrhagic fever virus, bluetongue virus, West Nile virus,
Schmallenberg virus, H. canis, L. infantum, Bunyamwera virus and Highlands J. virus have an overall
rate of introduction (being the combination of entry, vectorial transmission and establishment) in
each of the four EU regions of more than 0.001 overall introductions per year, for the other diseases,
the rate of introduction of VBD-agents was estimated to be lower.
Subsequently, if the combined overall rate of introduction exceeded 0.001 introductions per year
the annual extent of spread (taking into account the existing mitigation measures) was
calculated (TOR 2 and TOR 5). First, studies on the accuracy of the diagnostic tools to be used to
test animals before introduction, as described in the EU legislation, were reviewed. Also studies on the
efﬁcacy of vaccines, preventive and curative pharmaceutical treatments, as well as the mitigation
effect of vector control procedures authorised for use in the EU were reviewed. Then, it was identiﬁed
for which of the VBDs culling or movement restrictions are laid down in the EU regulations in case of
an outbreak. Then, the potential reduction of the probability of spread of the VBD was evaluated when
implementing the mitigation measures after an outbreak of a given VBD. The model estimated that the
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annual extent of spread after introduction of bluetongue virus, West Nile virus and Schmallenberg virus
in a previously free area would be moderate to very high, depending on the region. On contrary, the
model estimated that the annual extent of spread after introduction of H. canis, Crimean-Congo
haemorrhagic fever virus, L. infantum, Bunyamwera virus and Eastern equine encephalitis virus in a
previously free area would be very low.
Next, the probability of overwintering and the impact of disease were assessed (TOR 4).
The model estimated the probability of overwintering of Crimean-Congo haemorrhagic fever virus and
West Nile virus to be very high in the four regions of the EU. H. canis and L. infantum were estimated
to overwinter with a high probability and Schmallenberg virus, Bunyamwera virus and bluetongue virus
with a moderate probability.
Finally, for those VBDs for which the overall rate of introduction exceeded 0.001, the possible
impact of the VBD on public health, animal health and the economic impact on farm
production were also assessed (TOR 3). A summary was provided on the biocidal products approved
by European Environmental Agency (ECHA) and their speciﬁcations about hazard statements (including
environmental ones) and Risk Characterisation Ratios are provided.
When combining the estimated size of the epidemic with the severity of the infections,
Schmallenberg virus and bluetongue virus introductions were estimated by the model to cause a low
impact on animal health and welfare in S-and W-EU and very low in the other regions. For
H. canis, L. infantum, Eastern equine encephalitis virus, Crimean-Congo haemorrhagic fever virus,
Bunyamwera virus and West Nile virus the impact on animal health and welfare was estimated to be
very low everywhere in the EU.
The impact on production losses on infected farms with BTV was estimated to be very low to low
depending on the region in the EU. The impact of SBV was estimated to be moderate in S-and W-EU,
low in eastern EU and very low in N-EU. For all the other diseases there was either no impact on
production in the infected farms (L. infantum, H. canis, Crimean-Congo haemorrhagic fever virus and
West Nile virus) or there was no information available on the production losses in infected farms
(Bunyamwera virus and Eastern equine encephalitis virus). Note that this assessment considered only
potential losses due to the infection, and not due cost related to prevention and control measures.
The impact of the introduction of L. infantum in previously free areas on public health was
estimated to be very low. For the other diseases (Crimean-Congo haemorrhagic fever virus, West Nile
virus, Bunyamwera virus and Eastern equine encephalitis virus), there were not sufﬁcient data
available to assess the impact on public health.
To assess the potential impact on the environment of chemical biocidal products used to
control potential outbreaks of VBDs, information was extracted from ECHA’s website on approved
active substances which may be used for controlling the relevant vector species. Any potential impact
on the environment of the use of biocidal products beyond the intended uses, doses and target
species as evaluated by ECHA is unknown.
Due to the uncertainty related to some parameters used for the risk assessment (e.g. the biting
rate or vector competence of some vectors for certain uncommon VBD-agents, as well as the
prevalence of VBDs in endemic areas) or the instable or unpredictability disease situation in the source
regions, it is recommended to update the assessment as soon as new information becomes available.
Finally, as this risk assessment was carried out for large regions in the EU for a large number of
diseases, this assessment should be considered as a ﬁrst preliminary/rough screening. If a more
detailed risk assessment on VBDs is wished for on a national or subnational level, the in EFSA-VBD_
RISK model is freely available for this purpose.
Vector-borne diseases
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2017;15(5):4793
Table of contents
Abstract.................................................................................................................................................. 1
Summary................................................................................................................................................ 3
1. Background and Terms of Reference as provided by the requestor.................................................. 9
1.1. Background ................................................................................................................................ 9
1.2. Terms of Reference ..................................................................................................................... 10
2. Introduction................................................................................................................................ 10
2.1. Interpretation of the Terms of Reference....................................................................................... 10
2.2. Selection of vector-borne pathogens to be included in the risk assessment ...................................... 11
2.3. Selection of the regions potentially at risk and source areas of disease agents ................................. 13
2.4. Period for which the risk assessment was carried out ..................................................................... 15
2.5. Risk assessment framework ......................................................................................................... 15
2.6. The risk assessment model .......................................................................................................... 16
2.7. Assumptions and limitations ......................................................................................................... 17
2.8. Uncertainty ................................................................................................................................. 17
3. Characterisation of selected vector-borne diseases (ToR 1 and ToR 5) ............................................. 18
4. Overall rate of introduction (ToR 2)............................................................................................... 19
4.1. Worldwide occurrence of selected vector-borne diseases ................................................................ 19
4.1.1. Methodology to assess the worldwide occurrence of the VBD ......................................................... 19
4.1.1.1. Methodology to assess the geographic distribution of the VBD in the world ..................................... 19
4.1.1.2. Methodology to assess the probability that a new epidemic of a VBD would NOT be notiﬁed to the
OIE ............................................................................................................................................ 19
4.1.1.3. Methodology to assess the relative size of the infected areas.......................................................... 20
4.1.1.4. Methodology to assess the duration of the period of undetected spread.......................................... 20
4.1.1.5. Methodology to assess the frequency of the epidemics .................................................................. 21
4.1.1.6. Methodology to assess the prevalence .......................................................................................... 21
4.1.2. Data to assess the worldwide disease occurrence .......................................................................... 21
4.1.2.1. Data used to assess the geographic distribution of the VBD in the world ......................................... 21
4.1.2.2. Below follows a brief interpretation of each question that needed to be answered to assess the
worldwide occurrence of the 36 VBDs and a short guidance for the scoring. The data needed to
answer these questions are described in Sections 4.1.2. and 4.1.2.2. Data used to assess the likelihood
of the VBD being notiﬁed to the OIE ............................................................................................... 22
4.1.2.3. Data used to assess the relative size of the infected area............................................................... 22
4.1.2.4. Data used to assess the duration of undetected spread.................................................................. 22
4.1.2.5. Data used to assess the frequency of the epidemics in the infected area......................................... 22
4.1.2.6. Data used to assess the prevalence .............................................................................................. 22
4.1.3. Assessment of the worldwide occurrence of the VBD ..................................................................... 23
4.2. Rate of entry of selected vector-borne diseases ............................................................................. 23
4.2.1. Methodology to assess the rate of entry........................................................................................ 23
4.2.1.1. Methodology to assess the total numbers of animals moved along the pathways ............................. 23
4.2.1.2. Methodology to assess the probability of passing through the preventive/control measures before or
during transport .......................................................................................................................... 23
4.2.1.3. Methodology to assess the probability that a viable VBD-agent is still present upon arrival in the
area at risk ................................................................................................................................. 24
4.2.2. Data to assess the rate of entry ................................................................................................... 25
4.2.2.1. Data used to assess the total numbers of animals moved along the pathway................................... 25
4.2.2.2. Data used to assess the probability of passing through the preventive/control measures before or
during transport .......................................................................................................................... 25
4.2.2.3. Data used to assess the probability that a viable VBD-agent is still present upon arrival in the area
at risk......................................................................................................................................... 26
4.2.3. Assessment of the rate of entry.................................................................................................... 26
4.2.4. Conclusions................................................................................................................................. 32
4.3. Level of transmission of selected vector-borne diseases.................................................................. 32
4.3.1. Methodology to assess the level of vectorial transmission ............................................................... 32
4.3.1.1. Methodology to assess the distribution of competent vectors in the area at risk ............................... 32
4.3.1.2. Methodology to assess the value of the Basic Reproduction Ratio ................................................... 33
4.3.1.3. Methodology to assess the which fraction of the host population is susceptible ................................ 34
4.3.2. Data to assess the level of vectorial transmission........................................................................... 34
4.3.2.1. Data used to assess the distribution of competent vectors in the area at risk................................... 34
4.3.2.2. Data used to assess the value of the Basic Reproduction Ratio ....................................................... 34
Vector-borne diseases
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(5):4793
4.3.2.3. Data used to assess which fraction of the host population is susceptible ......................................... 34
4.3.3. Assessment of the level of vectorial transmission ........................................................................... 34
4.3.4. Conclusions................................................................................................................................. 37
4.4. Probability of establishment of selected vector-borne diseases ........................................................ 37
4.4.1. Methodology to assess the probability of establishment.................................................................. 37
4.4.1.1. Methodology to assess the probability of infecting a ﬁrst local vector (1st transmission step) ............ 37
4.4.1.2. Methodology to assess the probability of infecting a ﬁrst indigenous host (given ﬁrst transmission to
an indigenous vector)? (2nd transmission step) ............................................................................. 38
4.4.2. Data to assess the probability of establishment ............................................................................. 38
4.4.2.1. Data used to assess the probability of infecting a ﬁrst local vector (1st transmission step) ................ 38
4.4.2.2. Data used to assess the probability of infecting a ﬁrst indigenous host (given ﬁrst transmission to an
indigenous vector) (second transmission step)............................................................................... 39
4.4.3. Assessment of the probability of establishment.............................................................................. 39
4.4.4. Conclusions................................................................................................................................. 41
4.5. Overall rate of introduction .......................................................................................................... 42
4.5.1. Conclusions................................................................................................................................. 43
5. Annual extent of spread of vector-borne diseases (ToR 2 and ToR 5) .............................................. 43
5.1. Methodology to assess the annual extent of spread ....................................................................... 43
5.1.1. Methodology to assess the average number of infection generations per vector season.................... 43
5.1.2. Methodology to assess the proportion of areas with vector presence and host presence................... 44
5.1.3. Methodology to assess to what extent vectors/hosts movement does contribute to short/long-
distance spread........................................................................................................................... 44
5.1.4. Methodology to assess the duration of the period of undetected spread.......................................... 44
5.1.5. Methodology to assess the relevant control measures and the impact of each on local and on long-
distance spread (ToR 5)............................................................................................................... 44
5.2. Data to assess the annual extent of spread ................................................................................... 44
5.2.1. Data to assess the average number of infection generations per vector season................................ 44
5.2.2. Data to assess the proportion of areas with vector presence and host presence............................... 45
5.2.3. Data to assess to what extent movement of vectors/hosts does contribute to short/long-distance
spread........................................................................................................................................ 45
5.2.4. Data to assess the duration of the period of undetected spread...................................................... 45
5.2.5. Data to assess the relevant control measures and the impact of each on local and on long-distance
spread........................................................................................................................................ 45
5.3. Assessment of the annual extent of spread (ToR 2) ....................................................................... 45
5.4. Conclusions................................................................................................................................. 46
6. Probability of overwintering of selected vector-borne diseases (ToR 4) ............................................ 46
6.1. Methodology to assess the probability of overwintering .................................................................. 46
6.1.1. Methodology to assess the likelihood of overwintering of the pathogen in the host during adverse
season........................................................................................................................................ 47
6.1.2. Methodology to assess the likelihood of vertical transmission of the pathogen in the host leading to
overwintering.............................................................................................................................. 47
6.1.3. Methodology to assess the likelihood of direct host-to-host transmission of the pathogen leading to
overwintering.............................................................................................................................. 47
6.1.4. Methodology to assess the how likely is survival of an infected vector during the adverse season...... 47
6.1.5. Methodology to assess the likelihood of vertical transmission of the pathogen in the vector .............. 48
6.2. Data to assess the probability of overwintering.............................................................................. 48
6.2.1. Data used to assess the likelihood of overwintering of the pathogen in the host during adverse
season........................................................................................................................................ 48
6.2.2. Data used to assess the likelihood of vertical transmission of the pathogen in the host leading to
overwintering.............................................................................................................................. 48
6.2.3. Data used to assess the likelihood of host-to-host transmission of the pathogen leading to
overwintering.............................................................................................................................. 48
6.2.4. Data used to assess the likelihood of survival of an infected vector during the adverse season.......... 48
6.2.5. Data used to assess the likelihood of vertical transmission of the pathogen in the vector.................. 48
6.3. Assessment of the probability of overwintering(ToR 4) ................................................................... 48
6.3.1. Conclusions................................................................................................................................. 49
7. Impact (ToR 3) ........................................................................................................................... 49
7.1. Impact on Animal Health and Welfare........................................................................................... 50
7.1.1. Methodology to assess the predicted impact on animal health and welfare ...................................... 50
7.1.2. Data to assess the impact on animal health and welfare ................................................................ 50
7.1.3. Assessment of the impact on animal health and welfare................................................................. 50
7.1.4. Conclusions................................................................................................................................. 52
Vector-borne diseases
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(5):4793
7.2. Impact on production in infected farms......................................................................................... 52
7.2.1. Methodology to assess the possible production losses due to the infection in case-farms .................. 52
7.2.2. Data to assess the impact on production losses ............................................................................. 52
7.2.3. Assessment of the impact on production in infected farms ............................................................. 52
7.2.4. Conclusions................................................................................................................................. 54
7.3. What is the impact on public health? ............................................................................................ 54
7.3.1. Methodology to assess the predicted impact on public health ......................................................... 54
7.3.2. Data to assess the impact on Public Health ................................................................................... 55
7.3.3. Assessment of the impact on public health.................................................................................... 55
7.3.4. Conclusions................................................................................................................................. 55
7.4. Impact on the environment.......................................................................................................... 55
7.4.1. Methodology to assess the predicted impact on the environment through the use of chemical
biocides ...................................................................................................................................... 55
7.4.2. Data to assess the environmental impact ...................................................................................... 55
7.4.3. Assessment of the impact on the environment through the use of chemical biocides ........................ 55
7.4.4. Conclusions................................................................................................................................. 56
8. Overall Conclusions...................................................................................................................... 57
References.............................................................................................................................................. 61
Abbreviations .......................................................................................................................................... 67
Appendix A – Pathways............................................................................................................................ 68
Appendix B – Data used to estimate the range of the Reproduction Ratio.................................................... 71
Appendix C – Clinical signs in experimentally infected animals with VBDs and calculations of severity score ... 74
Appendix D – Model outputs and their conﬁdence intervals ........................................................................ 77
Appendix E – Biocidal products................................................................................................................. 83
Vector-borne diseases
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2017;15(5):4793
1. Background and Terms of Reference as provided by the requestor
1.1. Background
The European Union (EU) is constantly under the threat of introducing new animal diseases in its
territory. The changing distribution of arthropod vectors can create the conditions for the vector-borne
animal diseases to enter and spread across the EU, with a variable speed, depending on the
epidemiology of each disease.
There are several vector-borne diseases and infections that entered, or re-entered, the EU in recent
times (e.g. bluetongue, West Nile fever and Schmallenberg virus) and the introduction routes have not
always been identiﬁed. The list of vector-borne diseases, including the most relevant zoonoses, which
could enter the EU and become endemic could be rather long but the likely impact may vary in its
signiﬁcance. Therefore these hazards need to be identiﬁed and ranked in relation to the risk they
represent for the EU.
This work should be done together with the identiﬁcation and ranking of the most relevant routes
of introduction for each pathogen. The work of the European Food Safety Authority (EFSA) should
focus primarily on diseases listed by the World Organisation for Animal Health (OIE) as well as
emerging diseases that are recognised as a serious threat for the EU.
There are several legislative acts in the EU that address vector-borne diseases from a horizontal
perspective, of which the most relevant ones are:
• Council Directive 82/894/EEC of 21 December 1982 on the notiﬁcation of animal diseases
within the Community which sets an obligation for Member States to notify the Commission of
the conﬁrmation of any outbreak of diseases listed in Annex I.
• Council Directive 90/425/EEC of 26 June 1990 concerning veterinary and zootechnical checks
applicable in intracommunity trade in certain live animals and products with a view to the
completion of the internal market that recognises a series of vector-borne disease being
subject to mandatory emergency action, including territorial restrictions.
• Council Directive 92/65/EEC of 13 July 1992 laying down animal health requirements governing
trade in and imports into the Community of animals, semen, ova and embryos which identiﬁes
diseases listed in Annex A as notiﬁable and requires that trade in speciﬁc species of animals
and their products be subject to speciﬁc health requirements.
• Council Directive 92/119/EEC of 17 December 1992 introducing general Community measures
for the control of certain animal diseases that foresees control and eradication measures for
certain vector-borne diseases, exotic to the EU, listed in Annex I.
The following EU legislative acts provide speciﬁc prescriptions related to bluetongue and African
horse sickness:
• Council Directive 2000/75/EC of 20 November 2000 laying down speciﬁc provisions for the
control and eradication of bluetongue.
• Commission Regulation (EC) No 1266/2007 of 26 October 2007 on implementing rules for
Council Directive 2000/75/EC as regards the control, monitoring, surveillance and restrictions
on movements of certain animals of susceptible species in relation to bluetongue.
• Council Directive 92/35/EEC of 29 April 1992 laying down control rules and measures to
combat African horse sickness which lays down animal health conditions for the movement
between Member States and importation from third countries of live Equidae.
• Council Directive 2009/156/EC of 30 November 2009 on animal health conditions governing
the movement and importation from third countries of Equidae, which also takes into account
the situation on African horse sickness.
The risk manager is in need of updated scientiﬁc advice in order to assess the risk of introduction
of new vector-borne diseases and to determine if further measures are needed. This is linked to the
existence of a potentially devastating effect in case these diseases were to enter in the EU. The
existence of the current control measures need to be considered when identifying and ranking the
documented and likely entry routes into the EU. The outcome of this work will assist the Commission
in prioritising the use of resources for preventive actions in the ﬁeld of animal diseases.
Vector-borne diseases
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2017;15(5):4793
1.2. Terms of Reference
1) Identify, rank and brieﬂy characterise the vector-borne diseases that present a risk for the
EU. This work should cover both animal diseases and relevant zoonoses that present a risk
for the EU because of their introduction, re-introduction or further spread.
2) For each disease identiﬁed in point 1, identify and rank possible pathways of
introduction (or re-introduction) and further spread into the EU and assess the potential
speed of propagation in the EU.
3) For each disease identiﬁed in point 1, detail the potential health consequences and
other impacts to the EU in relation to the existence of suitable vectors and their
interaction with local animal populations.
4) Assess the risk of each disease becoming endemic in the animal population in the EU.
5) Brieﬂy review the feasibility, availability and effectiveness of the main disease
prevention and control measures (e.g. diagnostic tools, biosecurity measures,
restrictions on the movement, culling, vaccination).
2. Introduction
2.1. Interpretation of the Terms of Reference
To answer ToR 1, a brief characterisation of each of the vector-borne diseases (VBDs) was
provided. The characterisation of the diseases included: a description of the disease agent; basic facts
about the most important vectors involved in the transmission and their possible occurrence in the EU;
the geographic distribution of the disease agent; a brief description of the available prevention and
control measures of the infection in animals; a short description of the possible impact on animal
health and public health and a brief summary of the risk assessment.
Subsequently, the rate of entry (1), the level of transmission (2) and the probability of
establishment (3) were assessed to address the second part of ToR 1. For those diseases where the
overall expected rate of introduction (4), being the combination of the rate of entry, the level of
transmission and the probability of establishment exceeded 0.0011 (1 introduction in 1,000 years), also
the annual extent of spread (5) was assessed.
To answer ToR 2, the rates of entry were ranked for each of the VBDs and the pathways for entry
of the pathogens with the highest rates were ranked and discussed. Secondly, the level of
transmission, the probability of establishment, as well as the extent of spread were ranked for all the
VBDs.
To answer ToR 3, those VBDs for which the overall rate of introduction exceeded 0.001, the
possible impact of the VBD on public health, animal health and the economic impact on farm
production were also assessed (7). A summary was provided on the biocidal products approved by the
European Chemicals Agency (ECHA) but an environmental impact assessment of their use was not
within the scope of this mandate.
To answer ToR 4, for each VBD for which the overall rate of introduction exceeded 0.001, also the
probability of overwintering (6) was assessed.
To answer ToR 5, ﬁrst studies on the accuracy of the diagnostic tools to be used to test animals
before introduction, as described in the EU legislation, were reviewed. Also, studies on the efﬁcacy of
vaccines and preventive and curative pharmaceutical treatments authorised for use in the EU were
reviewed. Then, it was identiﬁed for which of the VBDs culling or movement restrictions are laid down
in the EU regulations in case of a particular VBD outbreak. Then the potential reduction of the
probability of spread of the VBD was evaluated when implementing the mitigation measures to be
taken after an outbreak of a given VBD.
The following deﬁnitions are used in this opinion:
1) Rate of entry, i.e. the expected number of introductions of the pathogen per year.
2) Level of transmission, i.e. the extent at which the pathogen is able to be transmitted
from vertebrate host to vector and to vertebrate host in at least one location of the area at
risk during a speciﬁc time period in which climatic and environmental conditions are suitable
1 This low threshold was chosen because of (a) the high number (36) of VBD considered and (b) the uncertainty in the
assessment.
Vector-borne diseases
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2017;15(5):4793
for replication and spread of the pathogen (thus the level of transmission is evaluated for
the optimal situation).
3) Probability of establishment, i.e. the probability that the pathogen can spread from
vector to host and vice versa given the conditions of introduction (pathway, time and place).
4) Overall rate of introduction, i.e. the combination of the rate of entry, the level of
transmission and the probability of establishment.
If the overall rate of introduction is > 0.001 per year, the framework proceeds to
evaluate the:
5) Annual extent of spread, i.e. the extent to which the pathogen is able to spread in a
year during the vector season, considering both local dispersal and long-distance spread,
including spread through animal movements, accounting for the number of animals/herds
infected and the geographic area affected.
6) Probability of overwintering, i.e. the likelihood that the pathogen will assert itself in the
area at risk for a prolonged period (i.e. for more than 1 vector season), possibly resulting in
endemicity.
7) Impact of the disease being present in an area, being the combination of the impact
on animal health, the production losses on case farms; and the impact on public health
(expressed as disability-adjusted-life-years in humans).
2.2. Selection of vector-borne pathogens to be included in the risk
assessment
A set of selection criteria (Figure 1) was agreed upon with the requestor of the mandate, to
prioritise the pathogens for which the risk assessment had to be carried out. First, the assessment was
restricted to pathogens that are transported and biologically transmitted by arthropod vectors, such as
sandﬂies, mosquitoes, ticks or midges. Thus, pathogens that are borne by other vectors, e.g. rodent-
borne pathogens, or mechanically transmitted pathogens were excluded from this risk assessment.
Additionally, in the context of potentially ﬁne-tuning or updating animal health legislation, it was
suggested to focus the risk assessment on exotic pathogens (here deﬁned as a pathogen present in
maximum one region in the EU (see Section 2.3) affecting the most important livestock and pet
species. Exceptions on this latter selection criterion were bluetongue virus, Schmallenberg virus,
African swine fever virus and West Nile virus, which were also included in the risk assessment on
special request. Also, canine leishmaniosis was included, although it occurs in two EU regions, namely
S- and W-EU. Although they are not considered exotic, as they occur in more than one region in the
EU, it was considered important to evaluate the potential routes that may lead to introduction and
spread in the EU, and the efﬁcacy of the available control measures. Diseases that were transmitted
solely by tsetse ﬂies were also excluded as to date there is no evidence of the presence of these
vectors in the EU. Applying these criteria resulted in the identiﬁcation of 39 pathogens, of which 14 are
notiﬁable to the OIE (Table 1). During the data collection for the risk assessment, another three
disease agents (Semliki forest disease virus, Cocal virus and Ibaraki virus) were removed from the list
of selected diseases, as there was either no evidence found that the disease agents affect livestock or
pet species (Semliki forest disease) or they were considered the same species of other disease agents
already in the list (such as Cocal virus and Ibaraki virus, which were assessed together with vesicular
stomatitis virus and epizootic haemorrhagic disease, respectively). The remaining 36 VBDs were
characterised and the risk of introduction was assessed for all of them (Table 1).
Vector-borne diseases
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Arthropod-borne pathogen?
Biological transmission?
Pathogen replicates in the following livestock and pets  
species:  cale, sheep, goats, swine, equines, dogs or cats
Exoc pathogen, absent or currently present in only 1 
region* in the EU?
Pathogen not transmied by tsetse ﬂy?
Grouping of VBD-agent sub-types
Re-introducon of VBDs in the list based on explicit 
request from requestor
Assess probability of entry of 36 selected  VBDs
*UN-regions: see Section 2.3.
Figure 1: Selection criteria for including pathogens in the risk assessment
Table 1: Causative agents of vector-borne diseases selected using the criteria as shown in Figure 1
Nr Family Genus Species Acronym
OIE
notiﬁable
1 Asfarviridae Asﬁvirus African swine fever virus ASFV Yes
2 Bunyaviridae Nairovirus Crimean-Congo haemorrhagic fever
virus
CCHFV Yes
3 Bunyaviridae Nairovirus Nairobi sheep disease virus NSDV Yes
4 Bunyaviridae Orthobunyavirus Aino virus AINOV No
5 Bunyaviridae Orthobunyavirus Akabane virus AKAV No
6 Bunyaviridae Orthobunyavirus Bunyamwera virus CVV No
7 Bunyaviridae Orthobunyavirus Main drain virus MDV No
8 Bunyaviridae Orthobunyavirus Schmallenberg virus SBV No
9 Bunyaviridae Orthobunyavirus Shuni virus SHUV No
10 Bunyaviridae Phlebovirus Rift Valley fever virus RVFV Yes
11 Bunyaviridae Unassigned Bhanja virus BHAV No
12 Flaviviridae Flavivirus Japanese encephalitis virus JEV Yes
13 Flaviviridae Flavivirus St. Louis encephalitis virus SLEV No
14 Flaviviridae Flavivirus Wesselsbron virus WSLV No
15 Flaviviridae Flavivirus West Nile virus WNV Yes
16 Flaviviridae Flavivirus Alkhurma haemorrhagic fever virus AHFV No
17 Hepatozoidae Hepatozoon Hepatozoon canis Hepat No
18 Orthomyxoviridae Thogotovirus Thogoto virus THOV No
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2.3. Selection of the regions potentially at risk and source areas of
disease agents
It was agreed that separate risk assessments for the 28 individual EU Member States were not
feasible for all pathogens identiﬁed in Table 1. This risk assessment was carried out for regions and -
regions used by the United Nations.2 This subdivision was chosen because data on trade and host
populations are available for these administrative regions, whilst the proposed ecological divisions are
not yet sufﬁciently linked with the diseases. The potential source regions (Figure 2) of disease
agents are all UN regions in the world where the VBDs are endemic or epidemic at the risk
assessment.
Nr Family Genus Species Acronym
OIE
notiﬁable
19 Reoviridae Orbivirus African horse sickness virus AHSV Yes
20 Reoviridae Orbivirus bluetongue virus BTV Yes
21 Reoviridae Orbivirus Epizootic haemorrhagic disease
virus (epizootic haemorrhagic
disease virus and Ibaraki virus)
EHDV Yes
22 Reoviridae Orbivirus Equine encephalosis virus EEV No
23 Reoviridae Orbivirus Palyam virus KASV No
24 Reoviridae Orbivirus Peruvian horse sickness virus PHSV No
25 Reoviridae Orbivirus Yunnan orbivirus YUOV No
26 Rhabdoviridae Ephemerovirus Bovine ephemeral fever virus BEFV No
27 Rhabdoviridae Unassigned Kotonkon virus KOTV No
28 Rhabdoviridae Vesiculovirus Vesicular stomatitis virus (Indiana,
Cocal, Alagoas and New Jersey)
VSV No
29 Rickettsiaceae Ehrlichia Ehrlichia ruminantium Cowdr Yes
30 Togaviridae Alphavirus Eastern equine encephalitis virus EEEV Yes
31 Togaviridae Alphavirus Getah virus GETV No
32 Togaviridae Alphavirus Highlands J. virus HJV No
33 Togaviridae Alphavirus Middelburg virus MIDV No
34 Togaviridae Alphavirus Venezuelan equine encephalitis virus VEE Yes
35 Togaviridae Alphavirus Western equine encephalitis virus WEEV Yes
36 Trypanosomidae Leishmania Leishmania infantum CanL Yes
2 Composition of macrogeographical (continental) regions, geographical sub-regions, and selected economic and other
groupings, http://unstats.un.org/unsd/methods/m49/m49regin.htm#europe
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From the countries in the UN regions of Europe, only the Member States of the European Union
were considered. Thus, the regions potentially at risk in the European Union (Figure 3) for
which the risk assessment was carried out were:
• Northern EU (N-EU): Lithuania, Denmark, Latvia, Ireland, Finland, Estonia, Sweden, United
Kingdom;
• Southern EU (S-EU): Spain, Greece, Malta, Italy, Croatia, Slovenia, Portugal, Cyprus;
• Western EU (W-EU): Belgium, Netherlands, Luxembourg, France, Germany, Austria;
• Eastern EU (E-EU): Hungary, Poland, Czech Republic, Bulgaria, Slovakia, Romania.
The vector distribution, host density or transportation may be different within an EU region, leading
to an uncertainty in the assessment.
Figure 2: Potential source regions of vector-borne diseases: regions of the United Nations
Vector-borne diseases
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2.4. Period for which the risk assessment was carried out
This assessment was carried out in 2016 and was based on trade data, published scientiﬁc
literature and the global disease occurrence available until 1 March 2016. In the future, this risk
assessment will be updated on a regular basis in the light of new relevant information.
2.5. Risk assessment framework
Several frameworks or models exist to characterise a disease agent (e.g. Discontools, Phylum,
DEFRA), to assess the risk of introduction (e.g. Discontools, Phylum, AHVLA), to assess the level of
transmission and spread of VBD or their overwintering (e.g. Fischer et al., 2013). Additionally, several
frameworks exist to deal with the impact of animals’ disease after they have entered a previously free
area (e.g. ANSES, EC 2007, OIE-Phylum, Discontools, ECDC). The Framework developed to guide the
risk assessment of possible Emerging VEctor-borne disease Risks (FEVER) (De Vos, 2011) uses a
stepwise approach, helping the risk assessor to consider all relevant steps of the risk pathways. It was
considered ﬁt for the purpose of this mandate, as it covers most aspects of the terms of reference.
The basic steps of the risk pathways distinguished in FEVER are displayed in Figure 4.
Figure 3: Regions potentially at risk
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2.6. The risk assessment model
Based on the above described risk assessment framework ‘FEVER’, a Method to INTegrate all
relevant RISK aspects (MINTRISK) was developed in Excel and Visual Basic. A web based version
with a central database and using Csharp for underlying calculations has been created for practical use
and access. This tool is called the EFSA-VBD_RISK model. The tool allows for a systematic, semi-
quantitative risk assessment, which can be used for risk evaluation, risk comparison and risk ranking of
possible vector-borne diseases of livestock. The probability of each step of the risk pathway was
calculated. First, the rates of entry, level of transmission, and probability of establishment were
calculated separately, and then these three probabilities were combined into an overall rate of
introduction. Subsequently, if the combined overall rate of introduction exceeded 0.001 introductions
per year (which equals an entry score of 0.2 in the model), the annual extent of spread, the
probability of overwintering and the impact of disease were assessed.
The questions to be addressed in EFSA-VBD_RISK model to assess the probability for each step
mostly could be answered by choosing from qualitative categories (each with their own underlying
quantitative explanation) associated with three options for the uncertainty about this estimate. Monte
Carlo simulation was used to determine the overall uncertainty in the probability for each step of the
pathway and for the overall probability. For most of the questions, the answer categories were given
on a logarithmic scale and the outcomes were always expressed on a logarithmic scale. When using
logarithmic scales for the answer categories, the contrast between the categories become higher,
which makes it easier to choose amongst the most appropriate answer category. This results in more
distinguishable outputs values and a higher impact of the choices.
However, to communicate the answer categories and results, these are translated back into EFSA-
VBD_RISK qualitative terms, such as ‘very high’ or ‘high’. In the methodology Sections, the quantitative
meaning of the qualitative terms are described for each of the answer categories for those who are
more interested in the quantitative estimates as such.
As described in Figure 4, there are six steps in the risk pathway developed in the FEVER
framework: (1) rate of entry, (2) level of transmission, (3) probability of establishment, (4) annual
extent of spread, (5) probability of overwintering and (6) the impact of the disease being present in an
area. Before step 1, however, an assessment of the worldwide occurrence of the infection needs to be
undertaken (step 0).
Temporal and spatial effects
Step 6. Impact of 
disease
Step 5. Probability of 
overwintering
Step 4.Extent of 
Spread
Overall rate of 
introduction
Step 2. Level of 
transmission
Step 1. Probability of 
entry
Step 0. Global 
occurrence
Step 3. Probability of 
establishment
Figure 4: Framework used to assess the risk of 36 vector-borne diseases (amended from: De Vos
et al., 2011)
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The VBDs were ranked for each horizontal step of the risk assessment according to their decreasing
rate of entry, level of transmission and probability of establishment, the extent of spread and
probability of overwintering and impact. Additionally, for those VBDs with a high risk, the most
important factors leading to this high risk were discussed.
In the methodology sections, for each step of the risk assessment follows a detailed description of
all the questions of the EFSA-VBD_RISK model that needed to be addressed for each of the steps of
the risk pathways in the FEVER framework. To allow comparing or ranking of diseases for each step, a
uniform approach was needed. Therefore, data were aggregated and assumptions made, often
involving expert judgement. The level of uncertainty was estimated for each question/answer.
2.7. Assumptions and limitations
After the extensive literature reviews, as described in Section 4.3.2 and reported in (Braks et al.,
2017a), it was decided to limit assessment of the rate of entry only for risk pathways which could be
sufﬁciently quantiﬁed. Due to very scarce or inexistent knowledge on the numbers of potentially
infected vectors and wildlife species moving into the EU regions, it was decided to assess the rate of
entry only for potentially infected livestock species and pets (cats and dogs). For commodities, for
which a priori it was known that there would be no further transmission of the disease agents after
entry, either because exposure to susceptible hosts or vectors could be excluded (e.g. by importing
fresh meat from infected animals with strictly VBDs), or because the hosts were considered to be dead
end hosts, the rate of entry was not assessed.
For this last reason, the rate of entry through movement of infected humans with the zoonotic
VBD-agents was not assessed because humans are not considered to play a role as amplifying hosts
for any of the zoonotic disease agents amongst those listed in Table 1 based on current knowledge.
2.8. Uncertainty
Three uncertainty levels can be selected to describe the certainty when answering the questions in
the EFSA-VBD_RISK model, low, moderate and high. The model will sample a value from triangular
distributions with different ranges around the answer category according to the chosen uncertainty
level as visualised in Figure 5 for a ‘moderate’ answer category. The ranges around the answer
category are +/0.1 for low, +/0.3 for moderate and +/0.5 for high uncertainty. Values around the
‘moderate’ category are most likely to be drawn when a low uncertainty is selected; however, if high
uncertainty is selected, values far from the moderate category are also quite likely to be drawn due to
the two ‘fat tails’ of the distribution.
To answer each question in the EFSA-VBD_RISK model, data were collected as described in
Section 2.1. For those questions where no data were found in peer-reviewed research studies and no
data were provided from ofﬁcial institutions, the answer category ‘unknown’ was chosen. This answer
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Figure 5: Triangular distributions from which the EFSA-VBD_RISK model will sample according to
different levels of uncertainty
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was always paired with a high uncertainty. The uncertainly of an answer to a question in the model
was moderate, when there was very scarce information or it involved expert opinion of few experts
only. For all the other answers where data from ofﬁcial institutions or published scientiﬁc journals were
available, the uncertainty of the answers was considered to be low.
Given an example, when for Question 11 (see Section 4.3.1): ‘What is the estimated value of the
basic reproduction ratio?’ There was no information available about the reproduction number (R0) in
the literature based on passed outbreaks elsewhere or no data were found to calculate the
reproduction number, then ‘Unknown’ was chosen as answer, together with a high uncertainty. When
the R0 was already found, based on passed outbreaks in the same region for which the risk was to be
assessed, the appropriate answer range was chosen in which the published R0 was situated, together
with a low uncertainty. When, however the R0 needed to be calculated based on extrapolations of R0
from other regions, or based on parameters that were extrapolated from other regions, a moderate
uncertainty was chosen.
3. Characterisation of selected vector-borne diseases (ToR 1 and ToR 5)
A short characterisation of each of the diseases is given via the links in Table 2, including a
summary of the characteristics of the disease agent, the transmission, the geographic distribution, the
potential vectors involved, the impact of the disease on animal health and welfare and a summary of
the available prevention and control measures. Additionally, the results of the risk assessment are
summarised per disease.
Table 2: Characterisation of the selected vector-borne diseases
No Links to online characterisation of VBDs (Storymaps) Acronym
1 Characterisation of African horse sickness AHS
2 Characterisation of African swine fever ASFV
3 Characterisation of Aino virus infection AINOV
4 Characterisation of Akabane virus infection AKAV
5 Characterisation of Alkhurma haemorrhagic fever virus infection AHFV
6 Characterisation of Bhanja virus infection BHAV
7 Characterisation of bluetongue BTV
8 Characterisation of bovine ephemeral fever BEFV
9 Characterisation of Bunyamwera virus infection CVV
10 Characterisation of Crimean-Congo haemorrhagic fever CCHF
11 Characterisation of eastern equine encephalitis EEE
12 Characterisation of epizootic haemorrhagic disease EHDV
13 Characterisation of equine encephalosis EEV
14 Characterisation of Getah virus infection GETV
15 Characterisation of heartwater Cowdr
16 Characterisation of hepatozoonosis (H. canis) Hepat
17 Characterisation of Highlands J. virus infection HJV
18 Characterisation of Japanese encephalitis JEV
19 Characterisation of Kotonkan virus infection KOTV
20 Characterisation of leishmaniosis (L. infantum) CanL
21 Characterisation of main drain virus infection MDV
22 Characterisation of Middelburg virus infection MIDV
23 Characterisation of Nairobi sheep disease NSDV
24 Characterisation of Palyam virus (Chuzan disease) KASV
25 Characterisation of Peruvian horse sickness PHSV
26 Characterisation of Rift Valley fever RVF
27 Characterisation of Saint Louis encephalitis SLEV
28 Characterisation of Schmallenberg virus infection SBV
29 Characterisation of Shuni virus infection SHUV
30 Characterisation of Thogoto virus infection THOV
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4. Overall rate of introduction (ToR 2)
4.1. Worldwide occurrence of selected vector-borne diseases
4.1.1. Methodology to assess the worldwide occurrence of the VBD
Figure 6 displays six questions that needed to be answered in the EFSA-VBD_RISK model to assess
the occurrence of the 36 VBDs across the world (step 0 of the risk assessment framework, see
Figure 4).
Below follows a brief interpretation of each and a short guidance for the scoring. The data needed
to answer these questions are described in Section 4.1.2.
4.1.1.1. Methodology to assess the geographic distribution of the VBD in the world
The geographic distribution of each VBD has been grouped by UN region (see Section 2.3).
Therefore, if a disease occurred (either reported to the OIE, or published in scientiﬁc literature) in at
least one country within a UN region, then the entire UN region was marked as positive.
4.1.1.2. Methodology to assess the probability that a new epidemic of a VBD would NOT
be notiﬁed to the OIE
The probability that a new epidemic of a VBD would NOT be notiﬁed to the OIE equals to one for a
non-OIE-notiﬁable disease. For the notiﬁable diseases, it will depend on several factors such as the
effect on animal and/or public health and/or the economic impact or political willingness. A matrix was
developed (Table 3) to harmonise the judgements on the probability of not reporting and to choose
No Links to online characterisation of VBDs (Storymaps) Acronym
31 Characterisation of Venezuelan equine encephalitis VEE
32 Characterisation of vesicular stomatitis VSV
33 Characterisation of Wesselsbron virus infection WSLV
34 Characterisation of West Nile fever WNV
35 Characterisation of Western equine encephalitis WEEV
36 Characterisation of Yunnan orbivirus infection YUOV
1.What is the geographic distribution 
of  the VBD in the world?
2.How likely is it that the VBD is 
notified to the OIE?
3.What is the relative size of the 
infected area ?
4.What is the duration of undetected 
spread?
5.What is the frequency of the  
epidemics in the infected area?
6.What is the prevalence?
Figure 6: Steps to describe the worldwide disease occurrence of each of the VBD in the EFSA-
VBD_RISK model
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one of the probability ranges as they appear in the EFSA-VBD_RISK model. The items that are
inﬂuential for reporting were assumed to be hierarchical, i.e. the effect on public health was
considered the most important trigger for reporting the disease. Quantitative probabilities were
assigned using the logarithmic scale to express this hierarchy.
4.1.1.3. Methodology to assess the relative size of the infected areas
To evaluate the size of the infected areas (i.e. the size of the areas where outbreaks have occurred
between 2005 and 2016 relative to the total size of the positive UN regions) all of the OIE outbreak/
event notiﬁcation locations, have been linked to NUTS1, NUTS2, GAUL 1 or GAUL 2 geographical
layers using ArcGIS and considered as infected areas. In order to calculate the size of the infected
areas relative to the positive UN regions, the following fraction was used:
Infected areas (km2)=Total areas of positive UN regions (km2)
Based on the outcomes of the equation the appropriate classes of the EFSA-VBD_RISK model were
chosen (which were derived from square root of 10 log steps): Very small (< 0.01), Small (0.01–0.03),
Moderate (0.03–0.10), Large (0.1–0.3) and Very Large (> 0.3). For non-notiﬁable diseases, for which
the occurrence is only known from scientiﬁc publications, studying, e.g. the prevalence of the disease,
the relative size of the infected area was unknown.
4.1.1.4. Methodology to assess the duration of the period of undetected spread
The duration will depend on many factors, such as the length of the incubation period in individual
animals, the severity of the clinical signs, the capability of the farmers and the veterinarians to
recognise the clinical signs, the transmissibility of the disease agent, the functioning of the veterinary
services and laboratories, and some political and economic interests. Assuming the awareness of the
farmers, the capacity of the veterinary services and the laboratories, the political and economic
environment to be constant for all the diseases in a given country, the duration of the period of
undetected spread was considered a function of the probability of notifying (P_notiﬁed), the length of
the incubation period (both the extrinsic incubation period in the vector (EIP), and the intrinsic
incubation period in the host (IIP). The decision tree (Figure 7) was followed and the most appropriate
range for the undetected spread was chosen. When the disease is not notiﬁable, ‘very long’ was
chosen as an answer. When the disease is notiﬁable, the duration of undetected spread is dependent
on the length of the incubation periods (Intrinsic and extrinsic) and the probability of notifying the
disease. Depending on their relation, the most appropriate of the ﬁve classes was chosen.
Table 3: Matrix to assess the likelihood that an OIE notiﬁable VBD epidemic is not notiﬁed to the
OIE
Effect on
public health
Effect on
trade
Effect on farm
production
Effect on animal
health and welfare
No effect
Effect on public health < 0.2(a) < 0.2 < 0.2 < 0.2 < 0.2
Effect on trade < 0.2 0.2–0.9 0.2–0.9 0.2–0.9 0.2–0.9
Effect on farm production < 0.2 0.2–0.9 0.9–0.99 0.9–0.99 0.9–0.99
Effect on animal health
and welfare
< 0.2 0.2–0.9 0.9–0.99 0.99–0.999 0.99–0.999
No effect < 0.2 0.2–0.9 0.9–0.99 0.99–0.999 > 0.999
(a): Probabilities as they appear in EFSA-VBD_RISK model, using a logarithmic scale to assign the probability to the categories.
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4.1.1.5. Methodology to assess the frequency of the epidemics
The OIE’s summary of immediate notiﬁcations and follow-ups on the WAHID interface was used to
gather information on the frequency of epidemics. Each new ‘event notiﬁcation’ has been counted as
an epidemic, regardless of how many outbreaks occurred within each notiﬁcation. Each event reports
the country and the resolution date (if resolved) and these variables have been used to distinguish one
epidemic from another. The result of the frequency calculation was evaluated against the frequency
classes which were derived from a square root of 10 log steps: Very low (< 1 per 10 years), Low (1–3
per 10 years), Moderate (3–10 per 10 years), High (1–3 per year), Very high (Very high) and
unknown. For non-notiﬁable diseases, the answer was chosen to be ‘unknown’. The estimate for
frequency of epidemics caused by the VBDs was accompanied with a moderate uncertainty for the OIE
notiﬁable diseases, and with a high uncertainty for the not-notiﬁable diseases.
4.1.1.6. Methodology to assess the prevalence
The ranges of the prevalence values reported in the cross-sectional prevalence surveys carried out
in the different regions found by the scientiﬁc literature were aggregated for each VBD per animal
family and evaluated against the available prevalence classes in the EFSA-VBD_RISK model were used
to estimate the numbers of animals imported: Very low (< 1E-4), Low (1E-4 to 0.001), Moderate
(0.001–0.01), High (0.01–0.1), Very high (> 0.1) and unknown. Before doing so, seroprevalences were
transformed into prevalences of infectious animals in a population, by using the following equation3:
Prevalence of infectious animals ¼ Median Infectious Period Seroprevalence
Median duration of Immunity
:
The median duration of immunity was assumed to be equal to the average lifespan of the animals:
cattle (breeding: 60 months; slaughter 12 months), camels (390 months), horses (breeding
330 months, slaughter 20 months), swine (breeding 24 months, slaughter 10 month), sheep and
goats (breeding 24 months, slaughter 4 months), dogs (138 months) and poultry (layer 70 weeks,
broiler 6 weeks).
4.1.2. Data to assess the worldwide disease occurrence
To answer the six questions in the EFSA-VBD_RISK model to assess the occurrence of the different
VBDs across the world (Figure 6), the data items described below were collected. A summary of the
data that was used as input for the model is provided in the supporting material.
4.1.2.1. Data used to assess the geographic distribution of the VBD in the world
Information on disease distribution was collected from two source types:
Is the disease 
notifiable?
(IIP+EIP)/P_notifie
d
Undetected 
spread > 3 years)
Very long
Undetected 
spread < 1 months
Very short
Undetected spread: 
1–3 months
Short
Undetected spread: 
3 months–1 year
Moderate
Undetected 
spread: 1–3 years
Long
Undetected 
spread: > 3 years
Very long
yes no
Figure 7: Decision tree to choose the ranges for the duration of undetected spread
3 Assuming an endemic equilibrium and constant risk over the year. Seasonality was taken into account during the calculation of
the probability of establishment (Section 4.4.1).
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1) For diseases notiﬁable to the World Organisation for Animal Health (OIE) (Table 1), the
OIE’s WAHID Interface4 was used to gather information on disease distribution. Data were
recorded between 1 January 2005 and 1 March 2016.
The WAHID database contains information on the location and the duration of the
outbreaks, and whether the situation has been resolved or not. Each new ‘event notiﬁcation’
lists all geographic areas where outbreaks occurred or are occurring.
Additionally data of outbreaks that were reported to the OIE monthly or every semester
were collected to assess the occurrence of the VBDs. In general, the OIE notiﬁcation reports
the ﬁrst or second subdivision of a country i.e. the region or province. In Europe this
corresponds to either the NUTS1 or NUTS2 statistical subdivisions or for the rest of the
world, the GAUL 1 or GAUL 2 subdivisions.5 Point references were recorded whenever
reported, or otherwise the smallest administrative unit reported was recorded.
2) Data on the distribution of diseases that are not notiﬁable to the OIE were extracted from
websites and reports of international authorities (e.g. http://www.oie.int/, http://ecdc.e
uropa.eu/en/Pages/home.aspx and http://www.cdc.gov/) and through an extensive literature
search that was performed to identify and extract information on disease prevalence (see
section below). Case studies were also included in the disease distribution database.
4.1.2.2. Below follows a brief interpretation of each question that needed to be answered
to assess the worldwide occurrence of the 36 VBDs and a short guidance for the
scoring. The data needed to answer these questions are described in
Sections 4.1.2 and 4.1.2.2. Data used to assess the likelihood of the VBD being
notiﬁed to the OIE
The list of OIE notiﬁable diseases was consulted (see also Table 1). Additionally, a narrative
literature review was carried out to evaluate if the disease is zoonotic (see disease characterisation and
Section 7.3.1) and what effect an epidemic would have on trade (see Section 4.2.2.3 for measures
inﬂuencing trade)) and farm production (see Section 7.1.4 for production losses). To evaluate the
effect on animal health and welfare, a systematic review (Dorea et al., 2017) was carried out to
evaluate the clinical signs (see also Section 4.2.2.3 for description on data collected about the clinical
signs).
4.1.2.3. Data used to assess the relative size of the infected area
ESRI’s World Albers Equal Area Conic projection coordinates6 was used to calculate world land
surface areas.
4.1.2.4. Data used to assess the duration of undetected spread
To assess the duration of the undetected spread, the list of OIE notiﬁable diseases was consulted,
together with the probability of notifying the disease (Section 4.1.2.2). Additionally, data on the
intrinsic incubation period were collected through a systematic review (Dorea et al., 2017; see also
Section 4.2.2.1). Data on the extrinsic incubation period were collected by Braks et al. (2017b) (see
also Appendix A for a short summary).
4.1.2.5. Data used to assess the frequency of the epidemics in the infected area
The OIE’s WAHID Interface was consulted to gather information on outbreak frequency. Data were
recorded between 1 January 2005 and 1 March 2016.
4.1.2.6. Data used to assess the prevalence
An extensive literature search was performed using the Web of Knowledge database (ISI Thomson-
Reuters) using the following search string:
((“pathogen full name”) and (*prevalence OR incidence OR infection OR epidemiol* OR outbreak
OR surveillance OR monitoring OR basic reproduction number OR basic reproduction ratio)) from 1
January 2005 to 31 January 2016.
4 http://www.oie.int/wahis_2/public/wahid.php/Wahidhome/Home
5 The Global Administrative Unit Layers (GAUL) is an initiative implemented by FAO within the EC-FAO Food Security Programme
funded by the European Commission. The NUTS classiﬁcation (Nomenclature of territorial units for statistics) is a hierarchical
syshGem for dividing up the economic territory of the EU.
6 Albers Equal Area Conic: http://webhelp.esri.com/arcgisdesktop/9.3/index.cfm?TopicName=Albers_Equal_Area_Conic
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At ﬁrst, titles and abstracts were screened to see if the study had the objective to study the
prevalence, incidence or occurrence of the pathogen or a previous exposure to the pathogen in an
area. In a second step, also the full texts were screened. Prevalence data were used if they were
obtained from prevalence surveys implementing a cross-sectional study design. The following
information was extracted from the included papers: number of animals sampled, number of animals
positive, host animal species; diagnostic test/assay types; sampling strategy; study type; reference
type and the geographic location of study. If studies did not report the diagnostic test, or the location
where the survey took place, they were excluded.
4.1.3. Assessment of the worldwide occurrence of the VBD
A summary of the data collected which was used as input for the EFSA-VBD_RISK model to answer
is provided in the Supporting Material. Maps of the geographic distribution of each of the 36 VBDs can
be found in the characterisation of the diseases (Section 3).
4.2. Rate of entry of selected vector-borne diseases
4.2.1. Methodology to assess the rate of entry
There are three questions that needed to be answered to assess the rate of entry (Step 1 of the
risk assessment framework, see Figure 4) of the 36 VBD-agents in the EFSA-VBD_RISK model
(Figure 8).
4.2.1.1. Methodology to assess the total numbers of animals moved along the pathways
The numbers of animals that moved into each of the four EU regions were grouped per family for
the mammals and per class for the birds (Equidae, Bovidae, Suidae, Canidae and Camelidae, and
aves). Animal species belonging to other families were not taken into account for this assessment. As
only the weights of the animals were reported per 100 kg, average weights of cattle (500 kg), camels
(500 kg), horses (400 kg), swine (350 kg), sheep (45 kg), goats (40 kg), dogs (20 kg) and cats
(4 kg), and poultry (2 kg) were used to estimate the numbers of animals imported.
Animals imported for slaughter and breeding purposes were considered separately as this may have
an impact on the probability of agent establishment (see Section 4.4.1).
The quantities extracted from EUROSTAT were then evaluated against the ranges provided in the
EFSA-VBD_RISK model: Minimal (< 100), Minor (100–1,000), Moderate (1,000–10,000), Major (10,000–
100,000), Massive (> 100,000). It should be noted that even when there was no trade reported to
EUROSTAT or TRACES, the minimum category includes a movement up to 100 animals, assuming that a
certain amount of unregistered movements of animals would always take place.
7.What are the total numbers /volumes of 
animals/commodities moved along the 
pathway?
•domestic animals
•biological 
material
•meat/products
8.What is the probability of passing 
through the preventive/control measures  
before/at transport?
•domestic animals
•biological material
•meat/products
9.What is the probability that a viable VBD-
agent is still present upon arrival in the area 
at risk?
•domestic animals
•biological material
•meat/products
Figure 8: Steps to describe the rate of entry each of the VBD in the EFSA-VBD_RISK model
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4.2.1.2. Methodology to assess the probability of passing through the preventive/control
measures before or during transport
To assess the rate of entry of a VBD-agent, ﬁrst the question whether the VBD-agent would persist/
survive despite the applied preventive/control measures before or during transport was dealt with.
More speciﬁcally, information was extracted from the EU legislation about which diseases must be
tested for at the export country, as well as information about the quarantine details and the veterinary
checks. Hence, the probability that a viable disease agent would be still present upon arrival of an
infected live animal in the EU equals approximately: (1  Sensitivity of the diagnostic
test) 9 (Probability of surviving the quarantine) (Figure 9). The probability of surviving the quarantine
would be approximately = exp[duration of the quarantine period/(latent period + infectious period)]. The
outcomes were evaluated against the classes provided by the EFSA-VBD_RISK model: Very low
(< 0.001), Low (0.001–0.01), Moderate (0.01–0.1), High (0.1–0.8) and Very high (> 0.8).
4.2.1.3. Methodology to assess the probability that a viable VBD-agent is still present
upon arrival in the area at risk
Secondly, the probability was assessed that a viable VBD-agent is still present upon arrival in the
area at risk. For live animals, this probability will depend on the duration of the journey, the duration
of the latent period and the duration of the infectious period of infected animals and it was
approximated by the following equation: equation: exp[duration journey/(latent period + infectious
period)] (Figure 10).
For commodities, the probability that a viable disease agent would still be present upon arrival in
the EU equals approximately = exp[duration of the journey/(maximum duration of survival in particular
matrix at given temperature)].
The calculated probabilities were then evaluated against the ranges provided in the EFSA-VBD_
RISK model: Very low (< 0.001), Low (0.001–0.01), Moderate (0.01–0.1), High (0.1–0.8) and Very high
(> 0.8).
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4.2.2. Data to assess the rate of entry
To answer the three questions in the EFSA-VBD_RISK model to assess the rate of entry of 36 VBDs,
the data items described below were collected. A summary of the data that was used as input for the
model is provided in the supporting material.
4.2.2.1. Data used to assess the total numbers of animals moved along the pathway
• Data on the number of livestock moved from 2011 to 2016 was extracted from EUROSTAT’s
COMEXT database that contains the ofﬁcial European Foreign Trade Statistics. All trade of live
animals is tied to speciﬁc health certiﬁcates that specify the purpose of a live animal being
imported (e.g. breeding and slaughter). Each certiﬁcate speciﬁes various preventive and
control measures that importers/exporters must meet in order to ship live animals.
• Data on the movement of dogs were extracted from TRACES.
4.2.2.2. Data used to assess the probability of passing through the preventive/control
measures before or during transport
An extensive literature review was carried out (Dorea et al., 2017 and Table A.1 in Appendix A) to
investigate experimental infection of susceptible hosts with each of the 36 VBD-agents and collect data
on their outcomes
• Incubation period: The median of the number of days between inoculation and ﬁrst reports
of clinical signs in the different studies, for each of the VBD subtypes in a host species. The
animals that showed no clinical signs were excluded.
• Median duration of latent period: The median of the number of days between inoculation
and ﬁrst isolation of virus in the different studies for each of the VBD subtypes in a host species.
Animals that were infected through transmission by direct contact with infected animals were
excluded from this calculation, because the exact moment of infection was unknown.
• Median duration of the infectious period: Median of the number of days when virus was
isolated for the last time in the different studies, for each of the VBD subtypes in a host
species, minus the median duration of the latent period. Only those studies that were not
terminated prematurely (i.e. the last observation was at least 3 days before the end of the
experiment) were included.
• Evidence of direct host-to-host transmission through experiments including contact
animals and excluding vectorial transmission.
• Evidence on transplacental transmission through detection of the virus in the fetus or in
the neonate, excluding experimental infection in utero and vectorial infection of neonates.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
Pr
ob
ab
ili
ty
 o
f p
as
si
ng
 th
e 
qu
ar
an
tin
e
Duration of journey (hours)
100 days
50 days
30 days
20 days
10 days
Latent + infectious
period
Figure 10: Probability that the VBD is still present upon arrival in the area at risk
Vector-borne diseases
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2017;15(5):4793
• Clinical signs7: Data about clinical signs were retrieved from the papers at the animal group
level. More in particular, when one or more animals in the group showed a particular sign, than
the group was counted as having this clinical sign.
4.2.2.3. Data used to assess the probability that a viable VBD-agent is still present upon
arrival in the area at risk
Survival time of the disease agents in different matrices
An extensive literature review and data collection relating to the survival time of each of the
disease agents was carried out (see Dorea et al., 2017 for review protocol). Data on maximum
duration of pathogen survival in several matrices were collected. The median was taken of the
maximum numbers of days reported in the different studies at which a particular VBD-agent was
isolated in a particular matrix.
Measures to prevent entry of disease agent in the EU
• Measures imposed on imports of animals and products from third countries
Information was recorded about speciﬁc requirements, e.g. which diseases must be tested for in
the export country, quarantine details, veterinary checks and commodity treatments such as heating
and freezing etc. Furthermore, information about the test types and methods prescribed to detect
speciﬁc pathogens were recorded in the database. (http://ec.europa.eu/food/animals/index_en.htm).
Other types of information regarding border inspection controls and transport requirements, such
as cleaning and spraying insecticides in shipping containers and aircrafts, were also recorded from the
EU legislation.
• Speciﬁcity and sensitivity of diagnostic tools
An extensive literature search and data extraction on the performance of diagnostic tools intended
to either demonstrate the presence or absence of infection (e.g. PCR, isolation of the pathogen), or to
detect evidence of a previous infection (e.g. antibodies) was performed for each of the VBDs listed in
Table 1 (Dorea et al., 2017). The lowest sensitivity of the obliged tests to detect a particular VBD-
agent before importing it into the EU, or before exporting it to another country in the EU were taken
for the risk assessment.
4.2.3. Assessment of the rate of entry
In Figure 11A–D, the entry scores of the VBDs through moving potentially infected livestock or pets
into each of the four EU regions are ranked from high to a low. A distinction was made if the animals
were moved for the purpose of breeding or slaughter into each of the regions in the EU. Further, it
was distinguished if the origin of the animals was outside (extra-EU), or inside the EU (intra-EU),
taking into account the different regulations applying for each of these pathways.
Only bars in the histogram in Figure 11A–D are visible for those VBDs with a rate of entry that was
not zero for the different pathways. Given an example, the model estimated that RVFV had a rate of
entry through livestock or pets either moved from inside and outside the EU, for breeding or slaughter,
of zero.
The model estimated that there is a high to very high rate of entry (1 entry per 10 years to 1 entry
per year) of CanL, Hepat, BTV, WNV, BHAV, CCHFV, SBV, THOV, EEV and VEE in all four EU regions
through movement of livestock or pets from infected regions in or outside the EU. Main parameters
contributing to the probability of entry are the prevalence of infection in susceptible hosts, the
numbers of animals moved into the EU and the probability that the pathogen is still present upon
arrival in the EU. The latter is determined mainly by the sensitivity of the tests (if testing is carried out)
and the infectious period in the hosts. There is a high uncertainty around the prevalence of some of
the VBDs in the source areas and the frequency of the outbreaks for not-reportable diseases.
Issues to take into account when interpreting the results of the assessment:
It should be noted that a high entry rate does not necessarily result in a high rate of introduction,
because the agent may not be transmitted or become established. Additionally, it should be taken into
account that for all VBDs an arbitrary default minimum of 100 susceptible animals were always
7 Clinical signs of infected animals in experimental studies are not reported in a uniform way. Often the number of animals with a
certain clinical sign is not mentioned. Also, in many cases, the ﬁrst or last day of individual animals showing particular clinical
sings are not mentioned in the papers.
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assumed to move into the EU regions in the model, when the import data had zero values. This should
allow for illegal movements of livestock, movement of wildlife and underreporting but may lead to a
slight overestimation of the rate of entry for some diseases especially for those with a single host
represented by large animal species. Whenever more than 100 animals were reported imported, these
reported data were used in the model.
At the same time, entry through the movement of vectors was not included in the assessment. The
probability of the entry of pathogens via the vector route is mainly determined by the life history of
the vector rather than the pathogen (Braks et al., 2017a). Considering available evidence, the highest
rate of entry of VBD-agents through the vector route is considered to be caused by attached tick
species. However, this route was assumed to be accounted for already through the movement of
infected animals on which they would be attached. The rate of entry of VBD-agents through other
routes (e.g. windborne movement of Culicoides or mosquitoes in containers) could not be assessed
due to the absence of quantitative evidence on their numbers moving into the EU, and their infection
rate (Braks et al., 2017a).
Finally, considering that entry of VBD-agents through the movement of wildlife species was not
included in the assessment due to the lack of quantitative data, the true rates of entry could be higher,
especially for those diseases affecting wild birds and connected migratory ﬂyways for wild birds (e.g.
WNV). Also, the rates of entry of disease agents present in regions neighbouring the EU, which are
connected through wildlife corridors, could have been underestimated (e.g. ASFV entry into E-EU).
The conﬁdence intervals around the outputs values visualised in Figure 11A–D can be found in
Table D.1 in Appendix D.
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4.2.4. Conclusions
• According to the model, there is a moderate/high to very high rate of entry (1 entry per
10 years to 1 entry per year) of CanL, Hepat, BTV, BHAV, WNV, SBV, THOV, CCHFV, EEV and
KASV in all four EU regions through movement of livestock or pets from infected regions inside
or outside the EU.
• A moderate rate of entry was estimated for CVV, PHSV, SLEV and YUOV in N-EU; for VSV, HJV
and SLEV in E-EU, for WEEV, CVV, EEEV, PHSV, YUOV and ASFV in W-EU; and for VSV, SLEV
and VEE in S-EU
• According to the model, there is low to very low rate of entry (less than 1 entry every
10,000 years) of AINOV, BEFV, AKAV, KOTV, MIDV, SHUV, WSLV, NSDV, EHDV, AHSV, GETV, JEV
and RVF.
4.3. Level of transmission of selected vector-borne diseases
4.3.1. Methodology to assess the level of vectorial transmission
There are three questions that needed to be answered to assess the level of transmission (Step 2
of the risk assessment framework, see Figure 4) of the 36 VBD-agents in the EFSA-VBD_RISK model
(Figure 12).
4.3.1.1. Methodology to assess the distribution of competent vectors in the area at risk
The distribution of the possible vectors for each of the VBD-agents was evaluated against the
classes of Table 4. Data for all the possible vector species were aggregated for each of the four EU
regions. Whenever one possible competent vector species was reported to occur in one of the
countries a given UN region, vectors were chosen to be ‘present’ in the UN region. When
entomological surveillance activities have been carried out to detect a given vector species, but this
could not be detected, than this vector species was recorded as absent. Whenever no entomological
surveillance was carried out to detect a vector species, then this species distribution was unknown
(Table 4). Finally, a fourth option was added, being the combination of vectors which were absent with
vectors for which the distribution was unknown.
10. What is the distribution of  possible 
competent vectors in the area at risk?
11.What is the estimated value of the 
basic reproduction ratio?
12. Which fraction of the host population 
is susceptible?
Figure 12: Questions to assess the level of transmission of a VBD-agent
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4.3.1.2. Methodology to assess the value of the Basic Reproduction Ratio
The R0 values delivered by the systematic review carried out by Braks et al., (2017b) are
summarised in Appendix A. The median values of the R0 were chosen to estimate the range of the R0
in the EU sub-region. When the review did not identify any published values of R0 for any of the
infected regions worldwide for a given VBD, then a proxy of the R0 was calculated. Therefore, the
parameters deﬁned below (A–E) had to be estimated and a proxy of R0 was calculated with the
following equation:
R0,proxy = Vectors per host 3 Biting rate^2 3 vector competence 3 EXP(EIP/expected
lifespan) 3 expected lifespan 3 Infectious period host
a) Vectors per host: estimates the expected ratio of vectors per host animals in the relevant habitat
and vector season. Since this exact ratio is generally unknown, the attack rate was used as a proxy
for this ratio. The latter is the number of vectors attacking a host at a given moment of time. The
following values of attack rates were used: 20 specimens for hard ticks per host, ﬁve specimens for
sandﬂies, 20 specimens for biting midges and ﬁve for mosquitoes (Braks et al., 2017a).
b) Biting rate: estimates the expected number of bites of a vector per day. For this assessment, the
average number of bites per lifetime over the duration over the expected lifespan of the vector was
used as proxy of the biting rate. This resulted in an average biting rate of 3/100 = 0.03 for hard
ticks, 10/21 = 0.48 for sandﬂies, 10/14 = 0.71 for biting midges and 10/21 = 0.48 for mosquitoes.
c) Vector competence: estimates the level of transmission from infectious host to vector 9 level of
transmission from infectious vector to host given that the vector bites the host. The ﬁrst
probability was estimated by taking the maximum of the numbers of infected vectors over the
numbers of exposed vectors to a disease agent from studies that were reviewed by VectorNet.
This information was provided in the External Scientiﬁc Report provided to EFSA by VectorNet
(Braks et al., 2017b) or in Appendix B.
d) Expected lifespan: estimates the average days a vector lives in the vector season. For this
assessment, the following values were used: 100 days for hard ticks, 21 days for sandﬂies,
14 days for biting midges and 21 days for mosquitoes. These values were based on Expert
opinion, and provided by VectorNet (Braks et al., 2017a).
e) Probability that the vector survives the extrinsic incubation period (EIP) in the vector
season, is estimated by the following formula:
Surv (EIP) = EXP(EIP/expected lifespan)
As a proxy for the EIP, the mean values per disease, forthcoming from the systematic review
carried out by VectorNet were used (table 4a in Braks et al., 2017b) or when there were no data
per disease, then the average of all the EIP per vector group were taken for this assessment
(table 4b in Braks et al., 2017b).
f) Infectious period in the host:
See Section 4.2.2.2.
The ranges of the obtained R0 from literature, or the calculated R0 were evaluated against the
ranges provided in the EFSA-VBD_RISK model: Very low (< 0.3), Low (0.3–1), Moderate (1–3), High
(3–10) and Very high (> 10).
Table 4: EFSA-VBD_RISK model classes for the distribution of possible vectors of the VBD-agents in
the EU regions
Absent Unknown Absent/unknown Present
The vector species in which the
VBD-agent was identiﬁed in
laboratory or in ﬁeld conditions
elsewhere in the world have not
been reported to occur in the
EU region, despite surveillance
efforts carried out to detect the
particular vector species
The vector species in
which the VBD-agent was
identiﬁed in laboratory or
in ﬁeld conditions
elsewhere in the world
have not been surveyed
in the EU region
The combination of either
vector species that are
absent, or vectors that
have not been surveyed
in the EU
At least one vector
species in which the VBD-
agent was identiﬁed in
laboratory or in ﬁeld
conditions elsewhere in
the world has been
reported to occur in the
EU region
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4.3.1.3. Methodology to assess the which fraction of the host population is susceptible
The fraction of susceptible hosts in a population depends on whether there has been a previous
infection with the same VBD-agent or with a similar pathogen that might cause some cross-protection.
Additionally, vaccination campaigns will reduce the number of susceptible hosts in the population.
Therefore, assuming a perfect vaccine the fraction of susceptible hosts in the population is an
approximation of 1 – (the fraction of immunised hosts by natural infection or vaccination).
The fraction of immunised hosts in the population will depend on the time that has passed since
the immunisation, the duration of the immunity, the efﬁcacy of the vaccines and the lifespan of the
immunised hosts (replacement). For populations where the VBD-agent has not entered before, or
where no vaccination takes place, this fraction will approach 0. For immunised populations, this will
approximate the seroprevalence.
The calculated probabilities were then evaluated against the ranges provided in the EFSA-VBD_
RISK model: Very low (< 0.03), Low (0.03–0.1), Moderate (0.1–0.3), High (0.3–0.8), Very high (> 0.8).
4.3.2. Data to assess the level of vectorial transmission
To answer the three questions in the EFSA-VBD_RISK model to assess the level of transmission of
the 36 VBDs, the data items described below were collected. A summary of the data that was used as
input for the model is provided in the supporting material.
4.3.2.1. Data used to assess the distribution of competent vectors in the area at risk
To generate data on the distribution of possible competent vector species of the 36 VBD-agents in
the four EU regions, an extensive literature review was carried out, identifying all possible vector
species in which at least one of the VBD-agents were identiﬁed in laboratory or in ﬁeld conditions.
Then, based on the identiﬁed literature, 21 experts judged if these species occur in the four regions in
the EU. Details for the review protocol and expert knowledge elicitation can be found here (Braks
et al., 2017a).
4.3.2.2. Data used to assess the value of the Basic Reproduction Ratio
An extensive literature review was carried out to identify studies with the objective to calculate the
basic reproduction ratio (see Braks et al., 2017b for search string). For studies using outbreak data, R0
during the peak of the vector season was used. For those studies that estimated the R0 based on
estimated transmission parameters, the R0 that represented the most ideal conditions for transmission
were used for the risk assessment.
When no published values of R0 were found for a given VBD-agent in any infected region in the
world, its value was estimated according to Koeijer et al. (2014). Therefore, an extensive literature
review was carried out to obtain information on the average numbers of vectors per host; the
average number of bites per lifetime; the duration over the expected lifespan; the median
vector competence and the extrinsic incubation period (see Braks et al., 2017a for the review
protocol, and Appendix A for a short summary of the results).
4.3.2.3. Data used to assess which fraction of the host population is susceptible
To evaluate which fraction of the population that could be susceptible to a particular VBD, data
were collected on the worldwide disease occurrence and seroprevalence (see Section 4.1.2.1).
4.3.3. Assessment of the level of vectorial transmission
Based on expert opinion (Vectornet 2016a), potential vectors of VBDs were considered to be absent
in the following EU regions and transmission would be impossible:
• E-EU: Cowdr, MIDV, NSDV, THOV and WSLV;
• N- EU: CanL, MIDV, NSDV, SHUV, VEE, WSLV and YUOV;
• S-EU: MIDV and WSLV;
• W-EU: AHFV, Cowdr, MIDV, NSDV, WSLV, YUOV.
On the other hand, the occurrence of potential vectors was unknown for the following VBDs in
each of the four EU regions:
• E-EU: AHFV, ASFV, BEFV, EEV, KASV, KOTV, PHSV, VSV, YUOV;
• N- EU: AHFV, ASFV, BEFV, Cowdr, EEV, KASV, KOTV, MDV, PHSV, THOV, VSV
Vector-borne diseases
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• S-EU: AHFV, Cowdr, KASV, KOTV, PHSV, VSV,
• W-EU: KASV, KOTV, PHSV, THOV, VSV
Figure 13 illustrates the estimated level of vectorial transmission of VBDs in each of the four EU
regions, ranking the diseases from a high to a low level of vectorial transmission.
The ﬁgure illustrates that the expected level of vector transmission of EHDV, KASV, BTV and EEV is
high in the four regions of the EU, with R0 values between 3 and 10. Several factors are contributing
to these high R0 values, such as the long infectious periods in the host reported in experimental
infections (e.g. medians of 17.5, 16.5, 21.3 and 16.5 dpi for EHDV, KASV, BTV and EEV, respectively).
Further, the high numbers of the vectors per hosts estimated (average of 20 vectors per host), the
high biting rate (0.51 on average) contributed to the high R0 values.
The level of vector transmission was estimated to be low to very low for CVV, EEEV, SHUV, VEE,
WEEV, GETV, HJV and MIDV everywhere in the EU with R0 values smaller than 0.3. For these VBDs the
estimated values of the numbers of vectors per host were much smaller (up to 5 vectors per host) and
the infectious period in the hosts reported in experimental infections was much shorter (e.g. medians
between 1 and 4 dpi).
For all the other VBD-agents, the level of transmission was expected to be moderate everywhere in
the EU (R0 between 1 and 3), except in W-EU where the level of transmission of AHFV, Cowdr, NSDV,
THOV and YUOV was estimated to be very low; in E-EU, it was estimated to be very low for BHAV,
Cowdr, NSDV; in S-EU, it was estimated to be very low for AHFV, and in N-EU, it was very low for
CanL, NSDV and YUOV.
It should be noted that the model only takes into account vector transmission.
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Issues to take into account when interpreting the results of the assessment:
With some exceptions for which good estimates of R0 have been published (e.g. BTV in northern,
W- and S-EU), the R0 values were associated with a moderate to high uncertainty, due to the lack of
documented data related to one or more of the parameters needed to calculate the ratio (such as the
biting rate, the vector competence or the extrinsic incubation period in the vectors). In fact, due to the
lack of data for some parameters, expert opinion was used to estimate the values at a general level
needed for each of the group of vectors (ticks, sandﬂies, biting midges and mosquitoes). Additionally,
for some of the VBD pathogens, the distribution of the potential competent vectors in the EU has
never been investigated. The conﬁdence intervals around the outputs values visualised in Figure 13
can be found in Table D.1 in Appendix D.
4.3.4. Conclusions
• The expected level of vector transmission of epizootic haemorrhagic disease virus, Palyam
virus, bluetongue virus and equine encephalosis virus was estimated to be high in the four
regions of the EU, with R0 values between 3 and 10.
• The level of vector transmission was estimated to be low to very low for Bunyamwera virus,
Eastern equine encephalitis virus, Shuni virus, Venezuelan equine encephalitis virus, Western
equine encephalitis virus, Getah virus, Highlands J. virus and Middelburg virus everywhere in
the EU with R0 values smaller than 0.3.
• For all the other VBD-agents, the level of transmission was expected to be moderate
everywhere in the EU (R0 between 1 and 3), except in W-EU where the level of transmission of
Alkhurma haemorrhagic fever virus, Ehrlichia ruminantium, Nairobi sheep disease virus,
Thogoto virus and YUOV was estimated to be very low; in E-EU (very low level of Bhanja virus,
Ehrlichia ruminantium, Nairobi sheep disease virus); S-EU (very low level of transmission of
Alkhurma haemorrhagic fever virus,) and N-EU (very low level of transmission of
Leishmania infantum, Nairobi sheep disease virus and Yunnan orbivirus).
4.4. Probability of establishment of selected vector-borne diseases
4.4.1. Methodology to assess the probability of establishment
There are two questions that needed to be answered to assess the probability of establishment
(Step 3 of the risk assessment framework, see Figure 4) of the 36 VBD-agents in the EFSA-VBD_RISK
model (Figure 14).
4.4.1.1. Methodology to assess the probability of infecting a ﬁrst local vector (1st
transmission step)
This probability can be interpreted as the probability of contact of the infectious animal or
commodity with a competent local vector or susceptible host respectively, hereby considering the
season, the location and purpose of movement/importation. The following considerations have been
used to guide this process:
For strictly vector-borne diseases, only the probability of contact of the imported host with local
vectors should be considered for the ﬁrst transmission step. The probability that the imported host will
get in contact with a local vector was therefore judged to be approximately equal to: (the proportion
13. What is the probability of infecting a first local 
(indigenous) vector or host, given the pathway of 
entry and the expected region and time of entry ? (1st 
transmission step)
14. What is the probability of infecting a first local 
vector (given first infection of an indigenous host) 
or host (given first infection of an indigenous 
vector)? (2nd transmission step)
Figure 14: Questions to assess the level of transmission of a VBD-agent
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of the vector season over the whole year) 9 (the proportion of imported hosts that are not for
immediate slaughter over all the imported hosts in the UN-region8) 9 (the proportion of the UN-region
with the vector presence).
The estimation of the proportion of animals that are not for immediate slaughter (within 5 days)
was also based on expert opinion. For animals imported for slaughter, it was assumed that only a very
small proportion would not be slaughtered. This proportion was estimated to be 0.1–0.5% of the
animals. On the other hand, for animals that are imported for breeding or production (it was assumed
that a high proportion would not be slaughtered within 5 days (between 90% and 95% of the
animals).
High vector presence was assigned when the summed maximum abundance of competent midge
vectors exceeded either 100 for Culicoides imicola or 1,000 for all other midge species Data were
collected through VectorNet, and modelled according to Versteirt et al. (2017). For those species
where no abundance data were available (sandﬂies, mosquitoes and ticks), high vector presence was
assigned to a location if the probability of presence of all competent vectors exceeded 80%. The
calculated probabilities were then evaluated against the ranges provided in the EFSA-VBD_RISK model:
Very low (< 0.0001), Low (0.0001–0.001), Moderate (0.001–0.01), High (0.01–0.1), Very high (> 0.1).
4.4.1.2. Methodology to assess the probability of infecting a ﬁrst indigenous host (given
ﬁrst transmission to an indigenous vector)? (2nd transmission step)
For strictly vector-borne diseases, assuming that the ﬁrst transmission step took place and a local
vector was infected, the probability that the infected local vector would get in contact with a local
susceptible host would depend on the proportion of the total UN region with the vector presence and
host presence. This proportion was calculated by overlaying the areas with the vector presence (see
previous step), and a high host density (more than 25 horses per km2 or more than 50 animals per
km2 for the other hosts). For these calculations, only host density data of horses, cattle, sheep, goats,
swine and deer were available. The calculated probabilities were then evaluated against the ranges
provided in the EFSA-VBD_RISK model: Very low (< 0.001), Low (0.001–0.01), Moderate (0.01–0.1),
High (0.1–0.8), Very high (> 0.8).
4.4.2. Data to assess the probability of establishment
To answer the two questions in the EFSA-VBD_RISK model to assess the probability of
establishment of 36 VBDs, the data items described below were collected. A summary of the data that
was used as input for the model is provided in the supporting material.
4.4.2.1. Data used to assess the probability of infecting a ﬁrst local vector (1st
transmission step)
• Vector season: The length of the duration of the vector season (Table 5) was obtained by
expert opinion. Twenty-one entomologist of VectorNet estimated the numbers of months when
adult vector activity can be expected at the southern and northern edges of each of the UN
regions.
• Purpose of imported animals:
 Animals imported for slaughter: trade of live animal reported to EUROSTAT Animals imported for breeding or production: trade of live animal reported to EUROSTAT
CN8 codes ending on 0 or 9.
Table 5: Numbers of months when adult vector activity can be expected (based on expert opinion)
N-EU E-EU S-EU W-EU
Mosquitoes 3–4* 3–9 8–12 4–8
Ticks 9–12 9–12 9–12 9–12
Sandﬂies 0–0 0–4 4–6 0–5
Biting midges 3–4 6–7 10–11 7–10
*: The numbers represent the number of months when adult vector activity can be expected at the northern and southern
edges, respectively.
8 The proportion of the vector season of the year was based on expert opinion (VectorNet knowledge matrix experts, 2016).
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• Data on the predicted vector presence (sandﬂies, ticks and mosquitoes) and abundance
(biting midges) was obtained from Braks et al. (2017a).
4.4.2.2. Data used to assess the probability of infecting a ﬁrst indigenous host (given ﬁrst
transmission to an indigenous vector) (second transmission step)
• Data on the host distribution were extracted from EUROSTAT.
4.4.3. Assessment of the probability of establishment
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Figure 15 illustrates the probability of establishment of VBDs in each of the four EU regions,
ranking the diseases from a high to a low probability of establishment. The ﬁgure illustrates the high
to very high probability of establishment of AKAV, BTV CCHFV, EEEV, EHDV, RVFV, SBV, WNV, WEEV in
all EU regions. Further the probability of establishment is only very high for WNV in W-EU and S-EU
and for AINOV only high in W-EU. GETV and JEV are moderate in N-EU, E-EU, and S-EU, while BHAV is
moderate only in E-EU and S-EU and AINOV, BEFV and CVV high to very high only in S-EU (with a
probability of 0.1–1 per introduction), depending on the region of the EU. For most of the other
diseases, the probability of establishment is estimated to be low to very low (with a probability of less
than 0.0001 per introduction).
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(a): Establishment scores: very low probability of establishment: 0–0.19; low probability of establishment: 0.2–0.39; moderate
probability of establishment: 0.4–0.59, high probability of establishment: 0.6–0.79, very high probability of establishment: ≥ 0.8.
(b): The establishment score represents the log transformed probability of establishment, where 1 represents certain
establishment, 0.8 translates to a probability of 10%, 0.6 translates to a probability of 1%, etc. The establishment score (sc)
translates into establishment probability using the following formula: Establishment_Probability = 10^[5 9 (sc  1)]. (c): AHSV:
African horse sickness virus; ASFV: African swine fever virus; AINOV: Aino virus; AKAV: Akabane virus; AHFV: Alkhurma
haemorrhagic fever virus; BHAV: Bhanja virus; BTV: Bluetongue virus; BEFV: Bovine ephemeral fever virus; CVV: Bunyamwera
virus; CCHF: Crimean-Congo haemorrhagic fever virus; EEE: Eastern equine encephalitis virus; EHDV: Epizootic haemorrhagic
disease virus; EEV: Equine encephalosis virus; GETV: Getah virus; Cowdr: Heartwater (Cowdriosis); Hepat: Hepatozoonis;
(H. canis); HJV: Highlands J. virus; JEV: Japanese encephalitis virus; KOTV: Kotonkan virus; CanL: Leishmaniosis (L. infantum);
MDV: Main Drain virus; MIDV: Middelburg virus; NSDV: Nairobi sheep disease virus; KASV: Palyam virus; PHSV: Peruvian horse
sickness virus; RVF: Rift Valley fever virus; SLEV: Saint Louis encephalitis virus; SBV: Schmallenberg virus; SHUV: Shuni virus;
THOV: Thogoto virus; VEE: Venezuelan equine encephalitis virus; VSV: Vesicular stomatitis virus; WSLV: Wesselsbron virus; WNV:
West Nile fever virus; WEEV: Western equine encephalitis virus; YUOV: Yunnan orbivirus virus.
Figure 15: ABCD Probability of establishment of vector-borne diseases in the four regions in the EU
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Issues to take into account when interpreting the results of the assessment:
In general, there is a much higher probability of establishment for animals which are imported for
breeding, compared to animals which are imported for direct slaughter upon arrival. Note also that this
assessment is only based on vector transmission (i.e. the establishment being the probability that the
pathogen can spread from vector to host and vice versa given the conditions of introduction (pathway,
time and place). The proportion of areas with a high vectors density could not be calculated for AHFV,
ASFV, Cowdr, Hepat, KASV, KOTV, MDV, MIDV, NSDV, PHSV, THOV, VSV as there is lack of spatial data
on the distribution of the vectors. Therefore, the probability of establishment of these diseases was
paired with a high uncertainty.
The conﬁdence intervals around the outputs values visualised in Figure 15 can be found in
Table D.1 in Appendix D.
4.4.4. Conclusions
• The model estimated the probability of establishment of Akabane virus, bluetongue virus,
Crimean-Congo haemorrhagic fever virus, Eastern equine encephalitis virus, epizootic
haemorrhagic disease virus, Schmallenberg virus, West Nile virus, Getah virus and Japanese
encephalitis virus to be high to very high (with a probability of 0.1–1 per introduction),
depending on the region of the EU.
• For most of the other diseases, the probability of establishment is estimated to be low to very
low.
• In general, there is a much higher probability of establishment after introduction by animals
which are imported for breeding, compared to animals which are imported for direct slaughter
upon arrival.
Vector-borne diseases
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CanL, CCHFV, BTV, WNV, SBV, Hepat, CanL and CVV and HJV have an overall rate of introduction
that is more than 0.001 overall introductions per year (or a score > 0.2). For these disease agents, the
annual extent of spread needed to be assessed.
In contrast, it was observed that some VBD-agents with a very high to moderate rate of entry, such
as BHAV, THOV, KASV, VEE, VSV or SLEV, had an overall rate of introduction that was very low, either
because there were no potential vectors present, or because the probability of exposure between the
vector and the susceptible host was too low, leading to a very low probability of establishment.
4.5.1. Conclusions
• According to the model, pathogens with a very high to risk of overall introduction are BTV,
CanL and CCHFV but not in the whole EU. Other pathogens such as WNV and SBV have
moderate risk of overall introduction.
• The model estimated that Crimean-Congo haemorrhagic fever virus, bluetongue virus, West
Nile virus, Schmallenberg virus, Hepatozoon canis, L. infantum, Bunyamwera virus and
Highlands J. virus have more than 0.001 overall introductions per year (or a score > 0.2). The
rate of introduction of all the other VBD-agents is lower.
5. Annual extent of spread of vector-borne diseases (ToR 2 and ToR 5)
5.1. Methodology to assess the annual extent of spread
There were six questions that needed to be answered to assess the annual extent of spread
(Figure 17) in the EFSA-VBD_RISK model (Step 4 of the risk assessment framework, see Figure 4).
Only for those VBDs for which the model estimated to be introduced (i.e. entered, transmitted and
established) at least once every 1,000 years, the annual rate of spread was estimated.
5.1.1. Methodology to assess the average number of infection generations per
vector season
The average number of vector infection generations in the vector season per UN region was
estimated by the following equation:
Average number of vector infection generations = number of days in active vector season/(extrinsic
incubation period (EIP)) + the latent period (host) + 0.5 9 (infectious periods of the vector) + 0.5 9
(infectious period the host)). For L. infantum, which can cause a very long infectious period in the
host, the infectious period in the host was replaced by the duration of the vector season- latent
period.
15.Average number of infecon generaons 
per vector season?
16.What is the proporon of areas  with 
vector presence and host presence?
17.To what extent does movement of 
vectors/hosts contribute to local/long-
distance spread?
18.What is the duraon of the period of 
undetected spread?
19. What is the eﬃcacy of control measures 
to stop local and/or long-distance spread?
Figure 17: Questions to assess the extent of spread of a VBD-agent
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For example, for Schmallenberg virus, in the W-EU region, with an average number of days in the
active vector season of Schmallenberg virus of 259.25 days per year, an average EIP of 10.29 days, an
average latent period of 2 days, an average lifetime of 14 days and an average infectious period in the
host of 6 days, the average number of infection generations in the vector season would be = =
(259.25)/(10.29 + 2 + ((14  10.29)/2) + (6/2)) = 15.12 generations per year.
5.1.2. Methodology to assess the proportion of areas with vector presence and
host presence
See second step of the establishment (Section 4.4.1.2).
5.1.3. Methodology to assess to what extent vectors/hosts movement does
contribute to short/long-distance spread
Both the active dispersal of vectors species and the animal movements in the EU reported to
EUROSTAT and TRACES were taken into account when addressing the extent of spread. The numbers
of susceptible host species moved between the EU regions are large, and it was assumed that they will
contribute to long distance spread of the VBD-agent when not controlled. The calculated probabilities
were then evaluated against the ranges provided in the EFSA-VBD_RISK model: Very low (< 1 km),
Low (1–3 km), Moderate (3–10 km), High (10–30 km) or Very high (> 30 km).
5.1.4. Methodology to assess the duration of the period of undetected spread
See Section 4.1.1.4.
5.1.5. Methodology to assess the relevant control measures and the impact of
each on local and on long-distance spread (ToR 5)
To assess the impact of the relevant control measures on the spread, measure has to be
implemented in case of an outbreak according to the EU legislation. Then, the expected coverage or
implementation of the measure (Ci) in the outbreak area was multiplied with its efﬁcacy (Ei) to obtain
the reduction of a given measure (Ri = 1/1  (Qi 9 Ei)). As data on the coverage or implementation of
the measures are scarce, these ﬁgures were based on expert opinion. The total reduction of R0 of all
possible measures together was considered to be an approximation of 1/the maximum reduction of all
the Ri (Table 6). The outcome of this evaluation was compared with the classes of the EFSA-VBD_RISK
model: Very low (< 0.15), Low (15–50%), Moderate (15–50%), High (75–90%), Very high (> 90%).
5.2. Data to assess the annual extent of spread
To answer the six questions in the EFSA-VBD_RISK model to assess the extent of spread the data
items described below were collected. A summary of the data that was used as input for the model is
provided in the supporting material.
5.2.1. Data to assess the average number of infection generations per vector
season
• Duration of the vector season: see Section 4.4.2.1.
• Intrinsic incubation period: see Section 4.2.2.2.
• Extrinsic incubation period: see Section 4.3.2.2.
Table 6: Implementation of different control measures and their efﬁcacy to reduce spread in case
of a VBD outbreak
Measure
Implementation/
coverage
Efﬁcacy
Reduction of
transmission
Restriction of movement C1 E1 1  (C1 9 E1) = R1
Culling C2 E2 1  (C2 9 E2) = R2
Vector control C3 E3 1  C3 9 E3) = R3
Vaccination C4 E4 1  (C4 9 E4) = R4
Treatments C5 E5 1  (C5 9 E5) = R5
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• Infectious period of host: see Section 4.2.2.2.
• Infectious period of vector (~ life span of the vector): see Section 4.3.2.2.
5.2.2. Data to assess the proportion of areas with vector presence and host
presence
Vector distribution: See Section 4.3.2.1.
5.2.3. Data to assess to what extent movement of vectors/hosts does contribute
to short/long-distance spread
Animal movements: See Section 4.2.2.1.
Active movements of vectors were reported by Braks et al. (2017a) up to 10 m for ticks, up to
100 m for sandﬂies, up to 1 km for biting midges and more than 1 km for mosquitoes.
5.2.4. Data to assess the duration of the period of undetected spread
See Section 4.1.2.4.
5.2.5. Data to assess the relevant control measures and the impact of each on
local and on long-distance spread
• The EU legislation for control measures after conﬁrmation of an outbreak: the applicable EU
legislation was reviewed and information was obtained for which VBD speciﬁc control
measures, such as movement restrictions and culling, are regulated see Section 4.2.2.3.
• Vaccine efﬁcacy: A systematic literature review was conducted looking into the efﬁcacy of
vaccines authorised for vaccinating animals in the EU (see Dorea et al., 2017, for review
protocol).
• Vector control measures: An extensive literature review was carried out to look into the active
substances that are approved by the European Environmental Agency concerning their target
species, their application and efﬁcacy (see Annex 2).
• Treatment efﬁcacy: A systematic literature review was carried looking into the efﬁcacy of
preventive and curative pharmaceutical treatments that are authorised for treating animals in
the EU (see Dorea et al., 2017, for review protocol).
5.3. Assessment of the annual extent of spread (ToR 2)
Figure 18 shows the model’s estimates for the annual extent of spread after introduction of a VBD
in a previously free area. Only BTV, WNV and SBV were estimated to have a moderate to very high
annual extent of spread, depending on the region, whereas the other disease outbreaks would stay
more localised. Results of BTV, WNV and SBV were mainly due to the high number of infection
generations, and the high overlap of high abundance host and vector areas.
For tick-borne diseases, such as CCHF and Hepatozoon canis, mainly the low number of infection
generations limits the extent of spread in the ﬁrst year after introduction. Also, for CanL, the estimated
number of infection generations per season was relatively low, but also the proportion of the
overlapping areas with high density of hosts and vector was estimated to be very low, leading to a low
spread. Finally, the combination of the application of topical insecticide together with vaccination was
considered to keep the spread of CanL low.
Issues to be taken into account when interpreting the results
It should be taken into account that to assess the potential extent of spread, it was assumed that
all available control measures were implemented. So the graph below should be interpreted, that even
when vaccinating and applying insecticides at the moment of suspicion and conﬁrmation of the
outbreak, BTV, WNV and SBV will still have a high to very high spread.
Additionally, it should be noted that there is a high uncertainty concerning the efﬁcacy of the
prevention and control measures of VBDs such as CVV, CCHF and HEPA. The conﬁdence intervals
around the outputs values visualised in Figure 18 can be found in Table D.1 in Appendix D.
Vector-borne diseases
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5.4. Conclusions
• The model estimated that the annual extent of spread after introduction of bluetongue virus,
West Nile virus and Schmallenberg virus in a previously free area would be moderate to very
high, depending on the region.
• The model estimated that the annual extent of spread after introduction of Hepatozoon canis,
Crimean-Congo haemorrhagic fever virus, L. infantum, Bunyamwera virus and Eastern equine
encephalitis virus in a previously free area would be very low.
6. Probability of overwintering of selected vector-borne diseases (ToR 4)
6.1. Methodology to assess the probability of overwintering
There were ﬁve questions that needed to be answered to assess the probability of overwintering
(Figure 19) in the EFSA-VBD_RISK model (Step 5 of the risk assessment framework, see Figure 4).
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Eastern Europe (EU countries only) Northern Europe (EU countries only)
Southern Europe (EU countries only) Western Europe (EU countries only)
Risk scores: very low annual extent of spread: 0–0.2; low annual extent of spread: 0.2–0.4; moderate annual extent of spread:
0.4–0.6, high annual extent of spread: 0.6–0.8, very high annual extent of spread: > 0.8. The annual extent of spread is a
logarithmic translation of the number of infected hosts that is expected to develop within one year. A risk score of 0 translates to
1 host, a score of 0.2 translates to 10 hosts, a score of 0.4 translates to 100 hosts, etc. and a score of 1 translates to 100,000
hosts. The annual extent of spread score (sc) translates into the number of infected hosts (units)/year (# infected hosts/year)
using the following formula: # infected hosts/year = 10^[5 9 sc]. BTV: Bluetongue virus; CVV: Bunyamwera virus; CCHFV:
Crimean Congo haemorrhagic fever virus; EEEV: Eastern equine encephalitis virus; Hepatozoonis; (H. canis); CanL: Leishmaniosis
(L. infantum); SBV: Schmallenberg virus; WNV: West Nile virus.
Figure 18: Annual extent of spread of vector-borne diseases in the four regions in the EU
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6.1.1. Methodology to assess the likelihood of overwintering of the pathogen in
the host during adverse season
The overwintering of the pathogen in the host was considered as the median duration of the
infectious period divided by the median duration of the adverse season. This proportion was compared
with the available classes in the EFSA-VBD_RISK model: Very low (< 0.1%), Low (0.1–1%), Moderate
(1–10%), High (10–80%) and Very high (> 80%).
6.1.2. Methodology to assess the likelihood of vertical transmission of the
pathogen in the host leading to overwintering
This likelihood was calculated as the (the prevalence) 9 (probability of vertical transmission) 9 (the
probability of being pregnant in the last trimester). When scientiﬁc evidence of vertical transmission
was found in scientiﬁc literature, an arbitrary probability of vertical transmission of ‘0.9’ was chosen.
The probability of being pregnant in the third trimester was chosen as the average number of
pregnancies per year for a given species, divided by 3. The outcome of the calculated probability of
vertical transmission was then compared with the available classes in the EFSA-VBD_RISK model: Very
low (< 0.1%), Low (0.1–1%), Moderate (1–10%), High (10–80%) and Very high (> 80%).
6.1.3. Methodology to assess the likelihood of direct host-to-host transmission
of the pathogen leading to overwintering
When evidence was found of direct host-to host transmission of the VBD-agent in scientiﬁc
literature, the highest class was chosen from the available classes in the EFSA-VBD_RISK model: Very
high (> 80%). When there was no evidence of direct host-to-host transmission the lowest class was
chosen: Very low (< 0.1%).
6.1.4. Methodology to assess the how likely is survival of an infected vector
during the adverse season
The probability of overwintering of vectors was calculated as the duration of the adverse season
over the life span of the vector. The outcome of the calculated probability of vertical transmission was
then compared with the available classes in the EFSA-VBD_RISK model: Very low (< 0.1%), Low (0.1–
1%), Moderate (1–10%), High (10–80%) and Very high (> 80%).
20. How likely is persistence of the 
pathogen in the host during adverse 
season (e.g. winter)?
21. How likely is  vertical transmission 
of the pathogen in the host leading to 
overwintering?
22. How likely is it that direct host-to-
host transmission of the pathogen leads 
to overwintering?
23. How likely is survival of an infected 
vector during adverse season (e.g. 
winter)?
24 How likely is vertical transmission of 
the pathogen in the vector?
Figure 19: Questions to assess the probability of overwintering of a VBD-agent
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6.1.5. Methodology to assess the likelihood of vertical transmission of the
pathogen in the vector
The probability of vertical transmission of the pathogen in the vector was reviewed by VectorNet for
the most important vector species for each VBD-agent (VectorNet, 2016). The probability was based
on expert opinion and compared with the classes provided in the EFSA-VBD_RISK model: Very low
(< 0.1%), Low (0.1–1%), Moderate (1–10%), High (10–80%) and Very high (> 80%).
6.2. Data to assess the probability of overwintering
To answer the ﬁve questions in the EFSA-VBD_RISK model to assess the probability of
overwintering the data items described below were collected. A summary of the data that was used as
input for the model is provided in the supporting material.
6.2.1. Data used to assess the likelihood of overwintering of the pathogen in the
host during adverse season
• Infectious period: see Section 4.2.2.2.
• Adverse season: see Section 4.4.2.1.
6.2.2. Data used to assess the likelihood of vertical transmission of the
pathogen in the host leading to overwintering
• Prevalence: see Section 4.1.2.1.
• Probability of vertical transmission in the host: see Section 4.2.2.2.
• Average number of pregnancies per year.
6.2.3. Data used to assess the likelihood of host-to-host transmission of the
pathogen leading to overwintering
• Results of contact transmission studies: see Section 4.2.2.2.
6.2.4. Data used to assess the likelihood of survival of an infected vector during
the adverse season
• Duration of the adverse season: see Section 4.4.2.1.
• Duration of the life span of the vector: see Section 4.3.2.2.
6.2.5. Data used to assess the likelihood of vertical transmission of the
pathogen in the vector
• Vertical transmission in vectors: see Section 4.3.2.2.
6.3. Assessment of the probability of overwintering(ToR 4)
The model estimated the probability of overwintering of CCHFV and WNV to be very high in the
four regions of the EU (Figure 20). This was mainly because for CCHFV direct transmission between
hosts was estimated to lead to a high probability of overwintering of the virus. Further, vertical
transmission in the vectors has been proven for both viruses and this mechanism is estimated to lead
to a high probability of overwintering of both pathogens.
The model estimated the probability of overwintering of HEPAT and CanL to be high in the four
regions of the EU. For CanL, both the persistence of the pathogen in the host, as well as vertical
transmission of the pathogen in the host was estimated to possibly lead to overwintering. For HEPAT,
both the persistence of the pathogen in the host, as well as the survival of the pathogen in the ticks
could lead to overwintering.
For BTV, CVV and SBV, the model estimated a moderate probability of overwintering. This was
mainly due to the possibility of vertical transmission in the host and the potential survival of the vector
in the adverse season (the latter only in S-EU).
Issues to be taken into account when interpreting the results:
There is a high uncertainty accompanied with some of the possible overwintering mechanisms.
More in particular, there was no published information on the vertical transmission of CCHFV and
Vector-borne diseases
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HEPAT in the host. Also, concerning vertical transmission of CVV in the vectors was no information
found. The conﬁdence intervals around the outputs values visualised in Figure 20 are reported in
Table D.1 in Appendix D.
6.3.1. Conclusions
• The model estimated the probability of overwintering of Crimean-Congo haemorrhagic fever
virus and West Nile virus to be very high in the four regions of the EU.
• The model estimated the probability of overwintering of H. canis and L. infantum to be high in
the four regions of the EU.
• The model estimated the probability of overwintering of Schmallenberg virus, Bunyamwera
virus and bluetongue virus to be moderate in the four regions of the EU.
• For EEEV, only in S-EU, the model estimated the probability of overwintering to be moderate
7. Impact (ToR 3)
There were three questions that needed to be answered to assess the impact (Figure 21) in the
EFSA-VBD_RISK model (Step 6 of the risk assessment framework, see Figure 4).
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Eastern Europe (EU countries only) Northern Europe (EU countries only)
Southern Europe (EU countries only) Western Europe (EU countries only)
Risk scores: very low probability of overwintering: 0-0.2; low probability of overwintering: 0.2–0.4; moderate probability of
overwintering: 0.4–0.6, high probability of overwintering: 0.6–0.8, very high probability of overwintering: > 0.8. The overwintering
score translates into a probability that the infection will persist through the winter. An overwintering score of 0.8 stands for nearly
certain persistence through the winter, if the epidemic enters the winter with about 100 infected hosts/vectors, a score of 0.6 stands
for a probability of 10%, a score of 0.4 stands for a probability of 1%. The overwintering score (sc) translates into the overwintering
probability using the following formula: overwintering probability = 10^[5 9 (sc  1)]. BTV: Bluetongue virus; CVV: Bunyamwera
virus; CCHFV: Crimean Congo haemorrhagic fever virus; EEEV: Eastern equine encephalitis virus; Hepatozoonis; (H. canis); CanL:
Leishmaniosis (L. infantum); SBV: Schmallenberg virus; WNV: West Nile virus.
Figure 20: Probability of overwintering of vector-borne diseases in the four regions in the EU
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7.1. Impact on Animal Health and Welfare
7.1.1. Methodology to assess the predicted impact on animal health and welfare
Currently, there is internationally a lack of consensus on methodologies to assess or quantify the
impact on animal health. In an attempt to provide and evidence based assessment, clinical signs as
extracted from the experimental infection studies (see Section 4.2.2.2 and Dorea et al., 2017 were
categorised by the AHAW Panel as either very severe, severe, moderate, mild, and very mild for an
example of clinical signs of BTV in sheep). In addition, ‘death’ was added as a separate category
indicating the biggest possible impact on animal health.
To enable the comparison of the impact on animal health and welfare of the different VBDs, a
severity score was calculated for each VBD. That is, for disease ‘a’ reporting n_{a,i} groups with
clinical signs ‘i’, the associated weight w_{a,i} was computed as: w_{a,i} = n_{a,i}/[sum of all n_{a,i}
over all disease (index a)]
The severity score (=aggregated severity over all clinical signs) for a disease ‘a’ was obtained by
S_a = [sum of C_i 9 w_{a,i} over all clinical signs (index i)]/[sum of all w_{a,i} over all clinical signs
(index i)], where C_i is the severity assigned to each clinical sign. The severity scores were then
inserted in the EFSA VBD risk assessment model as following: very mild (0.00–0.02), mild (0.02–0.07),
moderate (0.07–0.19), severe (0.19–0.44) and very severe (0.44–1.00).
These classes were chosen to reﬂect the understanding of a non-linear increase between
subsequent levels of severity of clinical signs e.g. severe clinics towards dead (see Appendix B). The
calculation used an exponential curve to deﬁne the increase with the exponent (here being 4) was
adapted to the most plausible understanding of severity levels for the animals.
It should be noted that there are still challenges to further standardise the approach. More in
particular, the assignment of clinical signs to the different categories of severity was merely guided by
expert opinion. Further, the way of reporting clinical signs in scientiﬁc literature is highly
heterogeneous, at time very detailed on the individual animal level, and at times general, on the
animal group level, using nonspeciﬁc terminology. Consequently, here we could only use signs reported
at the group level.
7.1.2. Data to assess the impact on animal health and welfare
• See Section 4.2.2.2 for data collection on clinical signs and Appendix C
7.1.3. Assessment of the impact on animal health and welfare
After calculating the severity score (see Appendix C) of the eight VBDs, which had an overall rate
of introduction that was higher than 0.001 per year, this score was combined with the epidemic size
(which is a combination of the extent of spread and the possibility of overwintering), to obtain a score
for the impact on animal health and welfare (see Figure 22).
25. What is the impact on animal health?
26. What is the impact on production in infected farms?
27. What is the impact on public health?
28. What is the imact on the environment through use ofchemical biocides  ?
Figure 21: Questions to assess the impact of a VBD-agent
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The model estimated SBV and BTV to have a low impact on animal health and welfare in the W-EU
and S-EU regions, whereas the impact was estimated to be very low in the other two regions of the EU
for these VBD-agents (Figure 22). It should be noted that the impact on animal health is the
combination of the severity score (being an indication of the severity of the clinical signs) combined with
the estimated epidemic size. The estimated epidemic size is a combination of the spread and possible
duration of the epidemic over more than 1 vector season (overwintering). Thus, the very mild and
moderate severity of a potential infection with SBV and BTV, respectively, were combined by the model
with the moderate to very large spread of the virus in previously uninfected areas (depending on the EU
region) and the moderate probability of overwintering in these areas for the two VBD-agents, resulting
in the low impact in the W-EU and S-EU regions, and very low in the other two regions of the EU.
For canine leishmaniosis (infections which can lead to severe clinical signs depending on the stage
of infection), the model estimated that the impact on animal health and welfare would be very low.
This was because the model estimated that the spread of the parasite in the hereto free areas would
be very low. The latter assumed the application of preventive measures (e.g. treatments with topical
insecticides or vaccination and curative treatments of infected dogs) after detection of the outbreaks.
For the other six VBD-agents, the impact was absent to very low everywhere in the EU, mainly due
to the limited spread predicted by the model and or the absence of clinical signs.
Issues to be taken into account when interpreting the results
Additionally, it should be noted that the uncertainty related to any of the previous steps will also
add up to the uncertainty related to the impact of the outbreaks on animal health and welfare as it
depends on the estimated size of the epidemic. Additionally, the uncertainty around the severity score
would reduce if clinical signs in animal experiments would be reported on an individual animal level
using speciﬁc terminology, instead of on the animal group level. The conﬁdence intervals around the
outputs values visualised in Figure 18 can be found in Table D.1 in Appendix D.
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Impact scores: very low impact: 0–0.2; low impact: 0.2–0.4; moderate impact: 0.4–0.6, high impact:
0.6–0.8, very high impact: > 0.8. BTV: Bluetongue virus; CVV: Bunyamwera virus; CCHFV: Crimean
Congo haemorrhagic fever virus; EEEV: Eastern equine encephalitis virus; Hepatozoonis; (H. canis);
CanL: Leishmaniosis (L. infantum); SBV: Schmallenberg virus; WNV: West Nile virus.
Figure 22: Impact on animals health and welfare of 8 VBDs with an overall rate of introduction that
was higher than 0.001 per year
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7.1.4. Conclusions
• When combining the size of the epidemic with the severity of the infections, Schmallenberg
virus and bluetongue virus introductions were estimated by the model to cause a low impact
on animal health and welfare in S-EU and W-EU, and WNF in S- EU.
• For H. canis, L. infantum, Eastern equine encephalitis virus, Crimean-Congo haemorrhagic
fever virus, Bunyamwera virus and West Nile virus, the model estimated the impact on animal
health and welfare to be very low everywhere in the EU.
7.2. Impact on production in infected farms
7.2.1. Methodology to assess the possible production losses due to the infection
in case farms
Based on the information collected about production losses (Table 7) during outbreaks, an expert
judgement was made, classifying the case farm production losses according to the classes in the EFSA-
VBD_RISK model and Table 7. Note that the production losses can be more than 100% because they
are not only the marginal losses to the infection but the infection could also result in culling of other
animals, or long-lasting economic losses, higher than the value of the farm at the moment of infection.
The economic impact due to the restrictions on trade or due to the costs of prevention and control
measures was not considered. Although these aspects can result in major economic consequences,
their impact assessment is resource intensive and was not within the scope of this mandate.
7.2.2. Data to assess the impact on production losses
Case farm production losses: a narrative literature review on production losses during outbreaks
(i.e. early culling, reduced milk production, weight loss and reproduction losses) was carried out.
7.2.3. Assessment of the impact on production in infected farms
Table 8 summarises the relative direct production losses on infected farms due to the VBD-agent
infection, which have been found in the scientiﬁc literature. Although for both BTV and SBV the
production losses on infected farms due to the disease were considered to be moderate, for all
the other diseases there were either no production losses due to the disease (WNF and CCHF), or the
disease did not affect production animals (CanL or Hepat), or there was no information found.
Table 7: EFSA-VBD_RISK model classes for the impact on case farm production losses
Impact on case-farm production (e.g. due to reduced
milk production, growth, mortality, etc.)
Qualitative
Classes for impact on
production losses in
case farms
0% of annual farm production is lost due to disease No impact 0
Up to 3% of annual farm production is lost due to disease Very Low impact 0–0.03
3–10% of annual farm production is lost due to disease Low impact 0.03–0.1
10–30% of annual farm production is lost due to disease Moderate 0.1–0.3
30–100% of annual farm production is lost due to disease High 0.3–1
More than 100% of annual farm production is lost due to disease Very High impact > 1
Unknown Unknown
Table 8: Results of narrative review on direct production losses in VBD infected farms
VBD-
agent
Impact on case-farm production (direct
losses due to disease)
Ref
Mintrisk
range
Uncertainty
BTV Between 0.3% and 0.9% loss of the annual milk
yield due to disease in cattle
Santman-Berends
et al. (2011)
Very low Low
BTV 3.4% loss of the annual milk yield due to disease
in cattle
Nusinovici et al.
(2013)
Low Low
BTV 20% loss of the annual milk yield due to disease in
cattle and sheep
Velthuis et al. (2010) Moderate Low
Vector-borne diseases
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The score of the overall production losses of each disease was then combined with the estimated
epidemic size to obtain the impact on production in the infected farms (Figure 23).
The impact on production losses of BTV was estimated to be low in the four regions of the EU. The
impact of SBV was estimated to be moderate in S-EU and W-EU, low in E-EU and very low in N-EU.
For all the other VBDs, there was either no impact, or there were no data available.
VBD-
agent
Impact on case-farm production (direct
losses due to disease)
Ref
Mintrisk
range
Uncertainty
BTV 0–3% early culling due to disease in cattle and
sheep
Velthuis et al. (2010) Very Low Low
BTV 7–8.1% weight loss due to disease in cattle and
sheep
Velthuis et al. (2010) Low Low
BTV 2.6–6.7% reduced birth weight due to disease in
cattle
Velthuis et al. (2010) Low Low
BTV 2–6.2% abortion due to disease in cattle and
sheep
Velthuis et al. (2010) Very Low Low
BTV 0–53.5% postponed gestation due to disease in
cattle and sheep
Velthuis et al. (2010) High Low
BTV Overall production losses due to disease in
infected farm
Expert opinion Moderate Moderate
CanL Not applicable (dogs) Expert opinion No impact Low
CCHFV Unapparent infection in most other vertebrate
hosts than humans
Expert opinion No impact Low
CVV Not found Unknown High
EEEV Not found Unknown High
Hepat Not applicable (dogs) Expert opinion No impact LOW
SBV 5–16% reduction of the gross margin due to
disease, mainly due to the costs of heifers and
steers not produced
Raboisson et al.
(2014)
Moderate Low
SBV 2–10% Median morbidity rate in cattle and small
ruminants
Martinelle et al.
(2014)
Low Low
SBV 53.3% increased rate of lamb mortality in ﬁrst
week due to disease in sheep
Saegerman et al.
(2014)
High Low
SBV 8.1% increased rate of malformations due to
disease in born lambs
Saegerman et al.
(2014)
Low Low
SBV 3.5% increased rate of abortions due to disease in
sheep
Saegerman et al.
(2014)
Low Low
SBV 0–53.5% postponed gestation due to disease in
sheep
Saegerman et al.
(2014)
High Low
SBV 50 decreased proliﬁcacy due to disease in sheep Saegerman et al.
(2014)
High Low
SBV Overall production losses due to disease in
infected farm
Expert opinion Moderate Moderate
WNV Up to 3% early culling due to disease in horses
based on the following information
(0.1 9 0.35 9 0.28 = 0.01)
10% Horse morbidity rate (infected horses that
will develop clinical signs of disease)
35% Hospitalisation rate for neurological cases
28% Horse case fatality rate (mortality among
neurological cases; the most severe cases being
hospitalised)
Leblond et al. (2007)
Weese et al. (2003)
Murgue et al. (2001)
Very low Low
WNV Overall production losses due to disease in
infected farm
Expert opinion Very low Moderate
Vector-borne diseases
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Issues to be taken into account when interpreting the results
It should be noted that for CVV and for EEEV there was no published information found about
direct production losses in infected farms. For those diseases where some peer-reviewed studies were
available, the uncertainty around the on farm production losses was moderate, due to the pooled
estimated of different production parameters. The conﬁdence intervals around the outputs values
visualised in Figure 18 can be found in Table D.1 in Appendix D.
7.2.4. Conclusions
• Possible production losses due to bluetongue outbreaks were estimated to be very low to low
depending on the region in the EU. The impact of Schmallenberg outbreaks was estimated to
be moderate in S-EU and W-EU, low in E-EU and very low in N-EU.
• For all the other VBD-agents, there was either no impact on production in the infected farms
(CanL, Hepat, CCHF and WNV) or there was no information available on the production losses
in infected farms (CVV and EEEV).
7.3. What is the impact on public health?
7.3.1. Methodology to assess the predicted impact on public health
Disability-adjusted life years (DALYs) are calculated to estimate the burden of disease by adding
years of life lost (YLLs) and years lived with disability (YLDs). YLLs represent the life years lost due to
death and are calculated by multiplying the number of deaths by a standardised expectation of
remaining life years at the age of death due to the disease. YLDs represent the life years lost due to
disability, adjusted for the severity of the disability. YLDs are computed for a given health outcome by
multiplying the prevalence of that outcome by a disability weight that has a value between 0
(equivalent to full health) and 1 (equivalent to death) (Mangen et al., 2013).
DALYs calculated to estimate the burden of disease for vector-borne diseases that affect public
health in other infected countries in the EU or elsewhere were used to judge on the possible burden of
disease in case a VBD-agent would enter, spread and possibly persist in a currently free region in
Europe. The DALY’s were then compared with the classes of the EFSA-VBD_RISK model for impact on
public health: Not zoonotic (0), Very low (< 3), Low (3–10), Moderate (10–30), High (30–100), Very
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Figure 23: Possible production losses on infected farms with VBDs with an overall rate of introduction
that was higher than 0.001 per year
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High (> 100). This estimate was assigned a high uncertainty due to different life expectancy, immune
status and health care facilities in the EU compared to the already endemic areas.
7.3.2. Data to assess the impact on public health
A narrative literature review was carried out to ﬁnd published information of possible outcomes of
DALY estimates (on 100,000 inhabitants) for those diseases that had an overall rate of introduction
that was higher than 0.001 per year and to provide an short description of the symptoms in humans.
7.3.3. Assessment of the impact on public health
Fifteen of 36 VBD could potentially affect humans (see Section 3 for the characterisation of the
diseases, including a brief section of the public health impact). For only ﬁve of those, the EFSA VBD
risk assessment model predicted an overall rate of introduction of more than 0.001 per year. Those
were WNV, CCHFV, CanL, CCV and EEEV. Up to date, only for cutaneous leishmaniosis scientiﬁc
literature could be found estimating the global burden of cutaneous leishmaniosis in DALYs, being 0.58
(0.26–1.12) per 100,000 people (Karimkhani et al., 2016), or very low when using the EFSA-VBD_RISK
model classes. For the other four zoonoses, the global public health impact is currently unknown.
Issues to be taken into account when interpreting the results
Although several studies are available on the clinical impact and the occurrence of these diseases,
there is currently no global assessment available combining the quantitative data on the incidence of
the diseases and the morbidity and mortality rates (with the exception of CanL). It should be stressed,
however, that the absence of studies calculating the burden of a disease does not mean that there is
no impact of the disease, but it has not been quantiﬁed so far. Therefore, the provision of a
meaningful model output on public health impact was at this stage not yet possible for these diseases.
7.3.4. Conclusions
The impact of the introduction of L. infantum in previously free areas on public health was
estimated to be very low. For the other diseases (Crimean-Congo haemorrhagic fever virus, West Nile
virus, Bunyamwera virus and Eastern equine encephalitis virus), there were either not sufﬁcient data
available to make any conclusion on the public health impact of new introductions of these diseases in
previously free areas.
7.4. Impact on the environment
7.4.1. Methodology to assess the predicted impact on the environment through
the use of chemical biocides
All biocidal products require an authorisation before they can be placed on the market, and the
active substances contained in that biocidal product must be previously approved by the ECHA. A
summary was provided on the biocidal products approved by ECHA but an environmental impact
assessment of their use was not considered within the scope of this mandate.
7.4.2. Data to assess the environmental impact
Information was extracted from ECHA’s website on approved active substances which may be used
for controlling the relevant vector species such as information on the target species, intended uses
(e.g. indoor/outdoor, professional/non-professional use), application/dose rate (i.e. efﬁcacy), hazard
class category and risk characterisation ratios (RCRs) (see Appendix D for more details).
7.4.3. Assessment of the impact on the environment through the use of
chemical biocides
The information collected as described in Section 7.4.2 and summarised in Appendix D deﬁnes the
speciﬁc intended uses and doses to be applied for the speciﬁed target species of the approved biocidal
products and the Hazard Statements and Risk Characterisation Ratios. Most of the products indicate no
risk for the environment, particularly those that intended for indoor use. The most frequent risk is that
of impact on aquatic organism if some of the products are not properly used and result in contact with
aquatic environments (i.e. Lambda-cyhalothrin and deltamethrin). Other products, such as insect
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growth regulators insecticides may also impact environment if contact with water bodies is not avoided
(i.e. diﬂubenzuron and pyriproxyfen). Some products massively used for controlling mosquitoes, such
as Bacillus thuringiensis (Bti) (200 tonnes annually worldwide, Becker, 1998) have shown no signiﬁcant
negative impact on the environment (Lagadic et al., 2014, 2016). Some indirect effects have been
observed in trophic chains, such as those between Diptera (i.e. Chironomida and Culicidae) and
Odonata (Jakob and Poulin, 2016). However, apart from the extensive literature on Bti, there is no
published data about the impact on the environment of general procedures conducted in regular basis
for vector control, particularly for chemical products (i.e. chemical treatments in stable, animals and
environment). However, since some of the products are also used in agricultural pest control programs
(i.e. deltamethrine), we could expect to have similar effects when those chemicals are applied in a
general way to the environment. Any potential impact on the environment of the use of biocidal
products beyond the intended uses, doses and target species as evaluated by ECHA is unknown.
7.4.4. Conclusions
• The Hazard Statements and Risk Characterisation Ratios of approved biocidal products indicate
the possible impact on the environment and non- targeted organism (i.e. soil biota, aquatic
organism, etc.) of the active ingredients according to its chemical composition, targeted
species and way of application.
• Any potential impact on the environment of the use of biocidal products beyond the intended
uses, doses and target species as evaluated by ECHA is unknown.
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8. Overall conclusions
Table 9: Qualitative model outputs for the steps pre-introduction
EU region
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AHFV E-EU H/VH L M VL/L VL
AHFV N-EU H/VH L M VL/L VL
AHFV S-EU H/VH L M VL/L VL
AHFV W-EU H/VH L VL VL/L VL
AHSV E-EU VL VL M VL/L VL
AHSV N-EU VL VL M VL/L VL
AHSV S-EU VL VL M VL/L VL
AHSV W-EU VL VL M VL/L VL
AINOV E-EU H/VH VL M VL VL
AINOV N-EU H/VH VL M VL VL
AINOV S-EU H/VH VL M M/H VL
AINOV H/VH VL M H/VH VL
AKAV E-EU M/H VL M H/VH VL
AKAV N-EU M/H VL M H/VH VL
AKAV S-EU M/H VL M H/VH VL
AKAV M/H VL M H/VH VL
ASFV E-EU VL H M VL/L VL
ASFV N-EU VL L M VL/L VL
ASFV S-EU VL H M VL/L VL
ASFV VL M M VL/L VL
BEFV E-EU H/VH VL M VL VL
BEFV N-EU H/VH VL M VL VL
BEFV S-EU H/VH VL M VL VL
BEFV H/VH VL M VL VL
BHAV E-EU H/VH VH VL/L M/H VL
BHAV N-EU H/VH VH M VL VL
BHAV S-EU H/VH VH VL/L M/H VL
BHAV H/VH VH M VL VL
BTV E-EU M VH H H/VH VH M/H M VL/L VL/L
BTV N-EU M VH H H/VH H/VH M/H M VL/L VL/L
BTV S-EU M VH H H/VH VH H M VL/L L
BTV M VH H H/VH H/VH H M VL/L VL/L
CanL E-EU VH VH M VL VL VL H VL VL
CanL N-EU VH VH VL VL VL VL M VL VL
CanL S-EU VH VH M M/H L/M VL/L H VL VL
CanL VH VH M VL/L VL VL H VL VL
CCHFV E-EU M/H VH M H/VH VL/L VL VH VL VL
CCHFV N-EU M/H M M H/VH L VL VH VL VL
CCHFV S-EU M/H VH M H/VH H/VH VL VH VL VL
CCHFV M/H VH M H/VH H VL VH VL VL
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Cowdr E-EU M L VL H/VH VL
Cowdr N-EU M L M VL/L VL
Cowdr S-EU M L M VL/L VL
Cowdr M L VL VL/L VL
CVV E-EU H/VH VL L VL VL/L VL M VL VL
CVV N-EU H/VH M L VL VL/L VL M VL VL
CVV S-EU H/VH VL/L L M/H VL/L VL H VL VL
CVV H/VH H/VH L VL VL/L VL M VL VL
EEEV E-EU L/M H/VH L H/VH L VL VL/L VL VL
EEEV N-EU L/M H/VH L H/VH VL/L VL VL/L VL VL
EEEV S-EU L/M H/VH L H/VH VL/L VL M VL VL
EEEV L/M M L H/VH L VL VL/L VL VL
EEV E-EU H/VH M/H H VL VL
EEV N-EU H/VH H/VH H VL VL
EEV S-EU H/VH M/H H VL VL
EEV H/VH H/VH H VL VL
EHD E-EU L VL H H/VH VL
EHD N-EU L VL H H/VH VL
EHD S-EU L VL H H/VH VL
EHD L VL H H/VH VL
GETV E-EU M/H VL VL M/H VL
GETV N-EU M/H VL VL M/H VL
GETV S-EU M/H VL VL M/H VL
GETV M/H VL VL H/VH VL
Hepat E-EU H/VH VH M VL/L VL VL H VL VL
Hepat N-EU H/VH VH M VL/L L/M VL/L H VL VL
Hepat_S-EU H/VH VH M VL/L L VL/L H VL VL
Hepat W-EU H/VH VH M VL/L L/M VL H VL VL
HJV E-EU H/VH M VL VL/L v
HJV N-EU H/VH L VL VL/L VL
HJV S-EU H/VH VL VL VL/L VL
HJV H/VH H VL VL/L VL
JEV E-EU VL/L VL M M/H VL
JEV N-EU VL/L VL M M/H VL
JEV S-EU VL/L VL M M/H VL
JEV VL/L VL M H/VH VL
KASV E-EU H/VH M/H H VL/L VL
KASV N-EU H/VH M/H H VL/L VL
KASV S-EU H/VH M/H H VL/L VL
KASV H/VH M/H H VL/L VL
KOTV E-EU H/VH VL M VL/L VL
KOTV N-EU H/VH VL M VL/L VL
KOTV S-EU H/VH VL M VL/L VL
KOTV H/VH VL M VL/L VL
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MDV E-EU M/H VL M VL/L VL
MDV N-EU M/H VL M VL/L VL
MDV S-EU M/H VL M VL/L VL
MDV M/H L M VL/L VL
MIDV E-EU H/VH VL VL VL/L VL
MIDV N-EU H/VH VL VL VL/L VL
MIDV S-EU H/VH VL VL VL/L VL
MIDV H/VH VL VL VL/L VL
NSD E-EU M/H VL VL VL/L VL
NSD N-EU M/H VL VL VL/L VL
NSD S-EU M/H VL M VL/L VL
NSD M/H VL VL VL/L VL
PHSV E-EU H/VH L M VL/L VL
PHSV N-EU H/VH M M VL/L VL
PHSV S-EU H/VH L M VL/L VL
PHSV H/VH M M VL/L VL
VL VL VL VL VL VL
RFV N-EU VL VL M H/VH VL
RFV S-EU VL VL M H/VH VL
RFV VL VL M H/VH VL
SBV E-EU H/VH VH M H/VH L/M H/VH M VL L/M
SBV N-EU H/VH VH M H/VH L/M L/M M VL VL
SBV S-EU H/VH VH M H/VH M/H H M L M
SBV H/VH VH M H/VH M/H VH M L M/H
SHU E-EU H/VH VL VL/L VL VL/L
SHU N-EU H/VH VL VL VL VL
SHU S-EU H/VH VL VL/L VL VL/L
SHU H/VH VL VL/L VL VL/L
SLEV E-EU M/H M M VL/L VL
SLEV N-EU M/H M M VL/L VL
SLEV S-EU M/H M M VL/L VL
SLEV M/H H M VL/L VL
THOV E-EU H/VH VH M VL/L VL
THOV N-EU H/VH VH M VL/L VL
THOV S-EU H/VH VH M VL/L VL/L
THOV H/VH VH VL VL/L VL
VEE E-EU L/M L/M VL/L VL VL/L
VEE N-EU L/M H VL VL VL
VEE S-EU L/M L/M VL/L VL VL/L
VEE L/M VH VL/L VL VL/L
VSV E-EU H M M VL/L VL
VSV N-EU H H M VL/L VL
VSV S-EU H M M VL/L VL
VSV H H M VL/L VL
WEEV E-EU M/H L VL/L H/VH VL/L
WEEV N-EU M/H VL VL/L H/VH VL/L
WEEV S-EU M/H VL VL/L H/VH VL/L
WEEV M/H M VL/L H/VH VL/L
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• According to the model, there is a moderate/high to very high rate of entry (1 entry per
10 years to 1 entry per year) of CanL, Hepat, BTV, BHAV, WNV, SBV, THOV, CCHFV, EEV and
KASV in all four EU regions through movement of livestock or pets from infected regions in or
outside the EU.
• The expected level of vector transmission of epizootic haemorrhagic disease virus, Palyam
virus, bluetongue virus and equine encephalosis virus was estimated to be high in the four
regions of the EU, with R0 values between 3 and 10.
• The level of vector transmission was estimated to be low to very low for Bunyamwera virus,
Eastern equine encephalitis virus, Shuni virus, Venezuelan equine encephalitis virus, Western
equine encephalitis virus, Getah virus, Highlands J. virus and Middelburg virus everywhere in
the EU with R0 values smaller than 0.3.
• For all the other VBD-agents, the level of transmission was expected to be moderate
everywhere in the EU (R0 between 1 and 3), except in W-EU where the level of transmission of
Alkhurma haemorrhagic fever virus, Ehrlichia ruminantium, Nairobi sheep disease virus,
Thogoto virus and YUOV was estimated to be very low; in E-EU (very low level of Bhanja virus,
E. ruminantium, Nairobi sheep disease virus); in S-EU (very low level of transmission of
Alkhurma haemorrhagic fever virus); and in N-EU very low level of transmission of
Leishmania infantum, Nairobi sheep disease virus and Yunnan orbivirus).
• The model estimated the probability of establishment of Akabane virus, bluetongue virus,
Crimean-Congo haemorrhagic fever virus, Eastern equine encephalitis virus, epizootic
haemorrhagic disease virus, Schmallenberg virus, West Nile virus, Getah virus and Japanese
encephalitis virus to be high to very high (with a probability of 0.1–1 per introduction),
depending on the region of the EU.
• For most of the other diseases, the probability of establishment is estimated to be low to very
low.
• In general, there is a much higher probability of establishment after introduction by animals
which are imported for breeding, compared to animals which are imported for direct slaughter
upon arrival.
• The model estimated that Crimean-Congo haemorrhagic fever virus, bluetongue virus, West
Nile virus, Schmallenberg virus, H. canis, L. infantum, Bunyamwera virus and Highlands J. virus
have more than 0.001 overall introductions per year (or a score > 0.2). The rate of
introduction of all the other VBD-agents is lower.
• The model estimated that the annual extent of spread after introduction of bluetongue virus,
West Nile virus and Schmallenberg virus in a previously free area would be moderate to very
high, depending on the region.
• The model estimated that the annual extent of spread after introduction of H. canis, Crimean-
Congo haemorrhagic fever virus, L. infantum, Bunyamwera virus and Eastern equine
encephalitis virus in a previously free area would be very low.
• The model estimated the probability of overwintering of Crimean-Congo haemorrhagic fever
virus and West Nile virus to be very high in the four regions of the EU.
• The model estimated the probability of overwintering of H. canis and L. infantum to be high in
the four regions of the EU.
WNV E-EU VL/L VH M H/VH M M/H VH VL VL
WNV N-EU VL/L VH M H/VH M L/M VH VL VL
WNV S-EU VL/L VH M VH M/H VH VH VL/L VL/L
WNV VL/L VH M VH M M VH VL VL
WSLV E-EU H/VH VL VL VL/L VL
WSLV N-EU H/VH VL VL VL/L VL
WSLV S-EU H/VH VL VL VL/L VL
WSLV H/VH VL VL VL/L VL
YUOV E-EU H/VH L M VL VL
YUOV N-EU H/VH M VL VL VL
YUOV S-EU H/VH L M VL/L VL
YUOV H/VH M VL VL VL
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• The model estimated the probability of overwintering of Schmallenberg virus, Bunyamwera
virus and bluetongue virus to be moderate in the four regions of the EU.
• For EEEV, only in S-EU, the model estimated the probability of overwintering to be moderate.
• When combining the size of the epidemic with the severity of the infections, Schmallenberg
virus and bluetongue virus introductions were estimated by the model to cause a low impact
on animal health and welfare in S-EU and W-EU, and West Nile virus in S-EU.
• For H. canis, L. infantum, Eastern equine encephalitis virus, Crimean-Congo haemorrhagic
fever virus, Bunyamwera virus and West Nile virus, the model estimated the impact on animal
health and welfare to be very low everywhere in the EU.
• Possible production losses due to bluetongue outbreaks were estimated to be very low to low
depending on the region in the EU. The impact of Schmallenberg outbreaks was estimated to
be moderate in S-EU and W-EU, low in E-EU and very low in N-EU.
• For all the other VBD-agents, there was either no impact on production in the infected farms
(CanL, Hepat, CCHF and WNF) or there was no information available on the production losses
in infected farms (CVV and EEEV).
• The impact of the introduction of L. infantum in previously free areas on public health was
estimated to be very low. For the other diseases (Crimean-Congo haemorrhagic fever virus,
West Nile virus, Bunyamwera virus and Eastern equine encephalitis virus), there were either
not sufﬁcient data available to make any conclusion on the public health impact of new
introductions of these diseases in previously free areas.
• Any potential impact on the environment of the use of biocidal products beyond the intended
uses, doses and target species as evaluated by ECHA is unknown.
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Abbreviations
AHAW EFSA Panel on Animal Health and Welfare
DALY Disability-adjusted life year
E-EU eastern European Union
ECHA European Chemicals Agency
EIP extrinsic incubation period in the vector
FEVER Framework developed to guide the risk assessment of possible Emerging VEctor-borne
disease Risks
GAUL Global Administrative Unit Layers
IIP intrinsic incubation period in the host
MINTRISK Method to INTegrate all relevant RISK aspects
N-EU northern European Union
NUTS Nomenclature of territorial units for statistics
OIE World Organisation for Animal Health
PEC Predicted Environmental Concentration
PNEC Predicted No Effect Concentration
R0 reproduction number
RCR risk characterisation ratio
S-EU southern European Union
TOR Term of Reference
VBD vector-borne disease
W-EU western European Union
YLD years lived with disability
YLL years of life lost
YUOV Yunnan orbivirus
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Appendix A – Pathways
Table A.1: Species considered for the pathways in the model
Disease
agent
Pathways: Species considered in the model*
AHFV Camel, sheep and goat
AHSV Equine
AINOV Cattle, sheep and goat
AKAV Cattle, sheep, goat and swine
ASFV Swine
BEFV Cattle
BHAV Cattle, sheep, goat
BTV Cattle, sheep, goat
CanL Dogs
CCHFV Cattle, sheep, goat and camel
Cowdr Cattle, sheep and goat
CVV Cattle, sheep, goat and equine
EEEV Birds (domestic turkeys, Live birds (excluding birds of prey, Psittaciformes, parrots, parakeets,
macaws, cockatoos, ostriches, emus and pigeons))
EEV Equine
EHD Cattle, sheep and goat
GETV Equine and swine
Hepat Dogs
HJV Birds (domestic turkeys, live birds (excluding birds of prey, Psittaciformes, parrots, parakeets,
macaws, cockatoos, ostriches, emus and pigeons))
JEV Swine
KASV Cattle, sheep and goat
KOTV Cattle
MDV Equine
MIDV Equine, sheep and goats
NSDV Sheep and goat
PHSV Equine
RVF Cattle, sheep, goat and camel
SBV Cattle, sheep and goat
SHUV Cattle, sheep, goat and equine
SLEV Birds (Gallus domesticus, domestic turkeys, domestic ducks, pigeons, live birds (excluding birds of
prey, Psittaciformes, parrots, parakeets, macaws, cockatoos, ostriches, emus and pigeons))
THOV Cattle, sheep, goat and camel
VEE Equine, swine, dogs
VSV Cattle, sheep, goat, swine, equine and camel
WEEV Birds (domestic turkeys, domestic ducks, pigeons, live birds (excluding birds of prey, Psittaciformes,
parrots, parakeets, macaws, cockatoos, ostriches, emus and pigeons))
WNV Birds (pigeons, live birds of prey, live domestic guinea fowls, live domestic, live ostriches and emus,
live birds (excluding birds of prey, Psittaciformes, parrots, parakeets, macaws, cockatoos, ostriches,
emus and pigeons))
WSLV Cattle, sheep, goat, equine and camel
YUOV Equine, sheep and goat
*: Dead end hosts were not considered in the pathways.
Vector-borne diseases
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Figure A.1: Rate of entry for the different diseases displayed per species groups
Table A.2: Medians values of parameters observed during experimental infections with VBDs in
animals
VBD
Median duration
latent period
Median duration of
infectious period
Median duration of
incubation period
Median duration
of clinical signs
AHS 4 10 6.5 9.5
AKAV 2 6 7 7
ASFV 3 12 3 11
BEFV 2 5 3.5 8
BTV 5 27 4 12.5
CanL 7 > 365 120 290
CCHFV 5 12 3 8
Cowdr 13.5 15.25 12 15
CVV 2 2 na na
EHDV 3 20.5 1 7
EEEV 1 5 na na
GETV 1 3 1.5 4.5
Hepat 28 43 na na
HJV 1 2.5 na na
Vector-borne diseases
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VBD
Median duration
latent period
Median duration of
infectious period
Median duration of
incubation period
Median duration
of clinical signs
JEV 2 4 5 8
RVFV 1 2 2 5
SBV na na 4.5 22
SLEV na 29 na na
VEE 1 4 1 8
VSV 1 162 2 13
WEEV 2.5 2.5 na na
WNV 1.5 10 na 1
WSLV 1.5 4 2 5
Source: Dorea et al. (2017).
Vector-borne diseases
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Appendix B – Data used to estimate the range of the Reproduction Ratio
Table B.1: Reproduction Ratios extracted from literature review (Braks et al., 2017b)
Pathogen
Reproduction
number*
Country Year** Bibliography
African swine fever 1.58 Russian
Federation
2015 Iglesias et al. (2016)
African swine fever 1.07*** Ukraine NR Korrenoy et al. (2016)
African horse sickness virus 2.6 United Kingdom 2006 Lo et al. (2013)
Bluetongue virus – serotype 8 2.3 Netherlands 2007 Santman Berends et al.
(2013)
Bluetongue virus – serotype 8 6.0 United Kingdom NR Gubbins et al. (2012)
Bluetongue virus 4 United Kingdom NR Gubbins et al. (2008)
Bluetongue virus 3.4 Austria 2009 Brugger et al. (2016)
Bluetongue virus 4.6 Austria 2009 Brugger and Rubel
(2013)
Bluetongue virus – serotype 8 4.0 Belgium 2006 de Koeijer et al. (2011)
Bluetongue virus – serotype 8 4.0 Germany 2006 de Koeijer et al. (2011)
Bluetongue virus – serotype 8 4.0 Netherlands 2006 de Koeijer et al. (2011)
Bluetongue virus – serotype 4.6 Spain 2007 Napp et al. (2016)
Bluetongue virus – serotype 8 22.0 Switzerland 2006 Racloz et al. (2008)
Bluetongue virus 3.1 South Africa NR Turner et al. (2013)
Crimean-Congo haemorrhagic
fever virus
1.2 Turkey 2013 Hoch et al. (2016)
Japanese encephalitis virus 1.2 Bangladesh 2009 Khan et al. (2014)
Leishmania infantum 1.1 Spain 1992 Amela et al. (1995)
Rift Valley fever virus 2.4 Egypt NR Gao et al. (2013)
Rift Valley fever virus 2.3 Unknown NR Chitnis et al. (2013)
Rift Valley fever virus 3.7 South Africa 2010 Xue et al. (2012)
Rift Valley fever virus 3.4 Unknown NR Mpeshe et al. (2011)
Rift Valley fever virus 6.8 United Republic of
Tanzania
2006 Mpeshe et al. (2014)
West Nile virus 7.0 Unknown NR Cruz-Pacheco et al.
(2005)
West Nile virus 15.3 United States 2004 Kilpatrick et al. (2006)
West Nile virus 89.4 Unknown NR Foppa and Spielman
(2007)
West Nile virus 1.6 United States 2003 Hartley et al. (2012)
West Nile virus 3.0 United States 2006 Pawelek et al. (2014)
*: For studies using outbreak data, the R0, calculated for the peak of the vector season were extracted. For those studies that
estimated the R0 based on estimated transmission parameters, the R0 that was calculated for the most ideal conditions for
transmission were extracted.
**: Start of the study.
***: Between-farm R0.
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Table B.2: Calculations of the proxy for the External Incubation Period derived from the literature
per disease/pathogen (a) and per vector group (b)
Disease Number of records
EIP*
Max Min Mean
African horse sickness virus 9 10 10 10.0
African swine fever virus 3 7 7 7.0
Bluetongue virus 44 12 7 9.9
Cache Valley virus 2 12 12 12.0
Epizootic haemorrhagic disease virus 22 14 10 10.3
Equine encephalosis virus 21 10 10 10.0
Getah virus 2 21 21 21.0
Highlands J virus 3 11 4 6.3
Japanese encephalitis virus 14 18 12 14.0
Leishmania infantum 3 7 5 5.7
Rift Valley fever virus 26 20 5 12.9
Schmallenberg virus 7 14 8 10.3
St. Louis encephalitis virus 10 14 12 13.6
Venezuelan equine encephalitis virus 17 25 10 13.7
Vesicular stomatitis virus 1 7 7 7.0
West Nile virus 120 65 2 15.1
Western equine encephalitis virus 8 14 4 12.3
Total 312
Vector group Number of records
EIP
Max Min Mean
Biting midges 105 14 7 10.0
Mosquitoes 199 60 4 14.0
Sand ﬂies 2 5 5 5.0
Ticks 6 65 2 22.2
Total 312
*: In case the range of the EIP instead of a point value was extracted from the papers, the mean value was considered for
computing.
Source: Braks et al., 2017b.
Table B.3: Vector Competence
Pathogen
Average vector
competence (%)
References
African horse sickness
virus
25 Venter et al. (2000), Venter and Paweska (2007)
African swine fever 100 de Carvalho Ferreira et al. (2014)
Bluetongue virus 22 Baylis et al. (2008), Venter et al. (1998, 2005, 2006), Paweska
et al. (2002), Veronesi et al. (2008)
Cache valley virus 60 Reeves and Miller (2013)
Epizootic haemorrhagic
disease virus
13 Paweska et al. (2005), Reeves et al. (2009), Ruder et al.
(2012)
Equine encephalosis
virus
12 Paweska and Venter (2004), Venter et al. (1999, 2002)
Getah virus 80 Takashima et al. (1983)
Highlands J virus 82 Borland et al. (2016)
Japanese encephalitis
virus
45 van den Hurk et al. (2003), Kramer et al. (2011), Huber et al.
(2014), Samuel et al. (2010), Johnson et al. (2009)
Leishmania infantum 60 Guimaraes et al. (2016), Seblova et al. (2012)
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Vector-borne diseases
Pathogen
Average vector
competence (%)
References
Rift Valley fever virus 17 Jupp et al. (2002), Kading et al. (2014), Moutailler et al.
(2007), Turell et al. (2007, 2008, 2010), Ndiaye et al. (2016)
Schmallenberg virus 13 Veronesi et al. (2013), Manley et al. (2015)
St. Louis encephalitis
virus
25 Reisen et al. (2005), Richards et al. (2007, 2009, 2012a,b)
Venezuelan equine
encephalitis virus
40 Deardorff and Weaver (2010), Moncayo et al. (2008), Smith
et al. (2005), Turell et al. (2006)
Vesicular stomatitis
virus
36 Drolet et al. (2005)
West Nile virus 62 Alto et al. (2014a,b), Anderson et al. (2010, 2012), Balenghien
et al. (2007, 2008), Bolling et al. (2012), Brustolin et al. (2016),
Ciota et al. (2013), Dodson et al. (2011, 2012), Eastwood et al.
(2011), Erickson et al. (2006), Fall et al. (2014), Fortuna et al.
(2015a,b), Fros et al. (2015), Goddard et al. (2002), Huber
et al. (2014), Hutcheson et al. (2005), Jansen et al. (2008),
Jiang et al. (2010), Kilpatrick et al. (2008, 2010), Kramer et al.
(2011), Lapointe et al. (2009), Lawrie et al. (2004), Lutomiah
et al. (2011), Micieli et al. (2013), Moudy et al. (2007), Reisen
et al. (2006a,b, 2008a,b), Richards et al. (2007a, 2010, 2011,
2012a,b, 2014), Sardelis et al. (2001), Sudeep et al. (2014),
Turell et al. (2002, 2005), Vaidyanathan and Scott (2007),
Vaidyanathan et al. (2008)
Western equine
encephalitis virus
50 Mahmood et al. (2006), Reisen et al. (2008a,b), Wang et al.
(2010, 2012)
Table B.4: Expert opinion on parameters needed to calculate the Reproduction Ratio
Parameters
Biting
midges
Sand
ﬂies
Hard
ticks
Mosquitoes
Expected number of vector bites per host (the attack rate
was used as proxy)
20 5 20 5
Expected number of bites 10 10 3 10
Expected lifespan 14 21 100 21
Biting rate = Expected number of bites/expected lifespan 0.71 0.48 0.03 0.48
Vector-borne diseases
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Appendix D – Model outputs and their conﬁdence intervals
Table D.1: Quantitative model outputs for the steps pre-introduction
Area potentially at risk Worldwide
occurrence 
Rate of entry Level of
transmission
Probability of
establishment
Overall  rate
of introduction
AHFV_Eastern_EU 0.81 (0.2; 1.38) 0.28 (-0.69; 1.19) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.03(-1.79; 0.4)
AHFV_Northern_EU 0.8 (0.22; 1.37) 0.25 (-0.68; 1.23) 0.5(0.03; 0.98) 0.16(-0.58; 0.9) -0.22(-1.85; 0.39)
AHFV_Southern_EU 0.8 (0.22; 1.37) 0.25 (-0.68; 1.23) 0.5(0.03; 0.98) 0.16(-0.58; 0.9) -0.22(-1.85; 0.39)
AHFV_Western_EU 0.81 (0.2; 1.38) 0.28 (-0.69; 1.19) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
AHSV_Eastern_EU 0.1 (-0.16; 0.35) -0.6 (-0.89; -0.3) 0.5(0.27; 0.73) 0.2(0.08; 0.32) -1.53(-1.9; 0.38)
AHSV_Northern_EU 0.1 (-0.16; 0.35) -0.6 (-0.89; -0.3) 0.5(0.42; 0.58) 0.2(0.08; 0.32) -1.59(-1.92; -1.28)
AHSV_Southern_EU 0.1 (-0.16; 0.35) -0.6 (-0.89; -0.3) 0.5(0.27; 0.73) 0.2(0.08; 0.32) -1.53(-1.9; 0.38)
AHSV_Western_EU 0.1 (-0.16; 0.35) -0.6 (-0.89; -0.3) 0.5(0.27; 0.73) 0.2(0.08; 0.32) -1.53(-1.9; 0.38)
AINOV_Eastern_EU 0.81 (0.43; 1.16) 0.11 (-0.26; 0.49) 0.5(0.27; 0.73) 0(-0.12; 0.12) -1.01(-1.46; 0.38)
AINOV_Northern_EU 0.8 (; ) 0.1 (; ) 0.5(0.27; 0.73) -0.4(; ) -1.5(; )
AINOV_Southern_EU 0.8 (; ) 0.1 (; ) 0.5(0.27; 0.73) 0.6(; ) -0.5(; )
AINOV_Western_EU 0.8 (; ) 0.1 (; ) 0.5(0.27; 0.73) 0.8(; ) -0.3(; )
AKAV_Eastern_EU 0.6 (; ) -0.1 (; ) 0.5(0.27;0.73 ) 0.8(; ) -0.5(; )
AKAV_Northern_EU 0.6 (; ) -0.1 (; ) 0.5(0.27;0.74 ) 0.8(; ) -0.5(; )
AKAV_Southern_EU 0.6 (; ) -0.1 (; ) 0.5(0.27;0.73 ) 0.8(; ) -0.5(; )
AKAV_Western_EU 0.6 (; ) -0.1 (; ) 0.5(0.27;0.73 ) 0.8(; ) -0.5(; )
ASFV_Eastern_EU 0.06 (-0.13; 0.28) 0.66 (0.46; 0.91) 0.5(0.42; 0.58) 0.17(-0.6; 0.89) -0.36(-1.17; 0.42)
ASFV_Northern_EU 0.06 (-0.13; 0.28) 0.26 (0.06; 0.51) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.6(-1.51; 0.38)
ASFV_Southern_EU 0.06 (-0.13; 0.28) 0.66 (0.46; 0.91) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.2(-1.11; 0.4)
ASFV_Western_EU 0.06 (-0.13; 0.28) 0.46 (0.26; 0.71) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.4(-1.31; 0.38)
BEFV_Eastern_EU 0.81 (0.43; 1.16) 0.11 (-0.26; 0.49) 0.5(0.03; 0.97) -0.6(-0.72; -0.48) -1.46(-2.04; 0.37)
BEFV_Northern_EU 0.81 (0.43; 1.16) 0.11 (-0.26; 0.49) 0.5(0.03; 0.97) -0.6(-0.72; -0.48) -1.46(-2.04; 0.37)
BEFV_Southern_EU 0.81 (0.43; 1.16) 0.11 (-0.26; 0.49) 0.5(0.03; 0.97) -0.2(-0.32; -0.08) -1.06(-1.64; 0.37)
BEFV_Western_EU 0.81 (0.43; 1.16) 0.11 (-0.26; 0.49) 0.5(0.03; 0.97) -0.2(-0.32; -0.08) -1.06(-1.64; 0.37)
BHAV_Eastern_EU 0.8 (0.22; 1.37) 1.05 (0.12; 2.03) 0.17(-0.6; 0.92) 0.6(0.49; 0.71) 0.12(-0.61; 1.15)
BHAV_Northern_EU 0.8 (0.22; 1.37) 1.05 (0.12; 2.03) 0.5(0.03; 0.98) -0.6(-0.71; -0.49) -0.29(-1.58; 0.37)
BHAV_Southern_EU 0.8 (0.22; 1.37) 1.05 (0.12; 2.03) 0.17(-0.6; 0.92) 0.6(0.49; 0.71) 0.12(-0.61; 1.15)
BHAV_Western_EU 0.8 (0.22; 1.37) 1.05 (0.12; 2.03) 0.5(0.03; 0.98) -0.2(-0.31; -0.09) 0.03(-1.18; 0.5)
BTV_Eastern_EU 0.5 (0.26; 0.74) 1.3 (1.03; 1.57) 0.68(0.42; 0.93) 0.8(0.69; 0.91) 0.89(0.57; 1.18)
BTV_Northern_EU 0.51 (0.26; 0.73) 0.91 (0.64; 1.15) 0.68(0.55; 0.78) 0.2(0.08; 0.31) -0.1(-0.39; 0.18)
BTV_Southern_EU 0.5 (0.26; 0.74) 1.3 (1.03; 1.57) 0.68(0.54; 0.78) 0.8(0.69; 0.91) 0.89(0.62; 1.19)
BTV_Western_EU 0.51 (0.26; 0.73) 1.31 (1.04; 1.55) 0.7(0.62; 0.78) 0.2(0.08; 0.31) 0.3(0.01; 0.58)
CanL_Eastern_EU 0.95 (0.61; 1.24) 1.04 (0.71; 1.35) 0.5(0.27; 0.73) 0(-0.12; 0.12) -0.08(-0.5; 0.38)
CanL_Eastern_EU 0.84 (0.63; 1.02) 1.14 (0.91; 1.36) 0.5(0.27; 0.74) 0(-0.11; 0.11) -0.02(-0.3; 0.38)
CanL_Northern_EU 0.95 (0.61; 1.24) 1.24 (0.91; 1.55) -6(-6; -6) -0.6(-0.72; -0.48) -6(-6; -6)
CanL_Southern_EU 0.95 (0.61; 1.24) 1.04 (0.71; 1.35) 0.5(0.42; 0.58) 0.6(0.48; 0.72) 0.44(0.09; 0.79)
CanL_Western_EU 0.95 (0.61; 1.24) 1.04 (0.71; 1.35) 0.5(0.27; 0.73) 0.2(0.08; 0.32) 0.12(-0.3; 0.39)
CCHFV_Eastern_EU 0.61 (0.15; 1.07) 1.2 (0.74; 1.68) 0.5(0.22; 0.73) 0.8(0.69; 0.91) 0.68(0.21; 1.26)
CCHFV_Northern_EU 0.61 (0.15; 1.07) 0.6 (0.14; 1.08) 0.5(0.69; 0.91) 0.8(0.69; 0.91) 0.27(-0.26; 0.67)
CCHFV_Southern_EU 0.61 (0.15; 1.07) 1.2 (0.74; 1.68) 0.5(0.42; 0.58) 0.8(0.69; 0.91) 0.8(0.33; 1.3)
CCHFV_Western_EU 0.61 (0.15; 1.07) 1.2 (0.74; 1.68) 0.5(0.27; 0.74) 0.8(0.69; 0.91) 0.71(0.25; 1.27)
Cowdr_Eastern_EU 0.51 (0.11; 0.89) 0.3 (-0.09; 0.71) -6(-6; -6) 0.16(-0.58; 0.9) -6(-6; -6)
Cowdr_Northern_EU 0.51 (0.11; 0.89) 0.3 (-0.09; 0.71) 0.5(0.03; 0.98) 0.16(-0.58; 0.9) -0.32(-1.47; 0.37)
Cowdr_Southern_EU 0.51 (0.11; 0.89) 0.3 (-0.09; 0.71) 0.5(0.03; 0.98) 0.16(-0.58; 0.9) -0.32(-1.47; 0.37)
Cowdr_Western_EU 0.5 (0.14; 0.88) 0.3 (-0.07; 0.7) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
CVV_Eastern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.3(0.07; 0.53) -0.4(-0.52; -0.28) 0.22(-1.84; 0.39)
CVV_Northern_EU 0.81 (0.2; 1.38) 0.5 (-0.09; 1.1) 0.3(0.07; 0.53) -0.6(-0.72; -0.48) 0.22(-1.64; 0.39)
CVV_Southern_EU 0.8 (0.22; 1.37) 0.16 (-0.45; 0.78) 0.3(0.07; 0.54) 0.6(0.49; 0.71) 0.22(-0.85; 0.39)
CVV_Western_EU 0.8 (0.22; 1.37) 0.5 (-0.09; 1.1) 0.3(0.07; 0.54) -0.2(-0.31; -0.09) 0.22(-1.32; 0.39)
EEEV_Eastern_EU 0.4 (0.04; 0.78) 0.3 (-0.09;0.71 ) 0.3(0.07; 0.53) 0.8(0.68; 0.91) 0.23 (-0.33;0.39 )
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EEEV_Northern_EU 0.4 (0.04; 0.78) 0.1 (-0.29; 0.51) 0.3(0.07; 0.53) 0.8(0.68; 0.91) 0.22(-0.53; 0.39)
EEEV_Southern_EU 0.4 (0.04; 0.78) 0.1 (-0.29; 0.51) 0.3(0.07; 0.53) 0.8(0.68; 0.91) 0.22(-0.53; 0.39)
EEEV_Western_EU 0.4 (0.04; 0.78) 0.5 (0.11; 0.91) 0.3(0.07; 0.53) 0.8(0.68; 0.91) 0.25(-0.13; 0.4)
EEV_Eastern_EU 0.81 (0.2; 1.38) 0.61 (0; 1.21) 0.7(0.47; 0.93) -0.6(-0.72; -0.48) -1.19(-1.81; -0.6)
EEV_Northern_EU 0.81 (0.2; 1.38) 0.81 (0.2; 1.41) 0.7(0.47; 0.93) -0.6(-0.72; -0.48) -0.99(-1.61; -0.4)
EEV_Southern_EU 0.81 (0.2; 1.38) 0.61 (0; 1.21) 0.7(0.47; 0.93) -0.2(-0.32; -0.08) -0.79(-1.41; -0.2)
EEV_Western_EU 0.81 (0.2; 1.38) 0.81 (0.2; 1.41) 0.7(0.47; 0.93) -0.6(-0.72; -0.48) -0.99(-1.61; -0.4)
EHD_Eastern_EU 0.3 (0.04; 0.56) -0.1 (-0.4; 0.19) 0.7(0.62; 0.78) 0.8(0.69; 0.91) -0.51(-0.81; -0.19)
EHD_Northern_EU 0.3 (0.04; 0.55) -0.1 (-0.38; 0.19) 0.7(0.62; 0.78) 0.8(0.68; 0.91) -0.49(-0.81; -0.2)
EHD_Southern_EU 0.3 (0.04; 0.56) -0.1 (-0.4; 0.19) 0.7(0.62; 0.78) 0.8(0.69; 0.91) -0.51(-0.81; -0.19)
EHD_Western_EU 0.3 (0.04; 0.55) -0.1 (-0.38; 0.19) 0.7(0.62; 0.78) 0.8(0.68; 0.91) -0.49(-0.81; -0.2)
GETV_Eastern_EU 0.61 (0.23; 0.96) -0.1 (-0.46;0.29 ) 0.16(0.03;0.34 ) 0.6(49; 0.71) 0.16(0.03;0.35 )
GETV_Northern_EU 0.61 (0.23; 0.96) -0.1 (-0.46;0.29 ) 0.16(0.03;0.35 ) 0.6(49; 0.71) 0.16(0.03;0.35 )
GETV_Southern_EU 0.61 (0.23; 0.96) -0.1 (-0.46;0.29 ) 0.16(0.03;0.34 ) 0.6(49; 0.71) 0.16(0.03;0.35 )
GETV_Western_EU 0.61 (0.23; 0.96) -0.1 (-0.46;0.29 ) 0.16(0.03;0.35 ) 0.8(0.68;0.91 ) 0.16(0.03;0.35 )
Hepatozoon_Eastern_EU 0.8 (0.46; 1.16) 1.1 (0.74; 1.46) 0.48(-0.01; 0.98) 0.16(-0.58; 0.9) 0.13(-0.68; 0.75)
Hepatozoon_Northern_EU 0.8 (0.46; 1.16) 1.7 (1.34; 2.06) 0.5(0.03; 0.98) 0.16(-0.58; 0.9) 0.36(-0.08; 1.35)
Hepatozoon_Southern 0.8 (0.46; 1.16) 1.5 (1.14; 1.86) 0.5(0.03; 0.98) 0.16(-0.58; 0.9) 0.28(-0.28; 1.15)
Hepatozoon_Western 0.8 (0.46; 1.16) 1.7 (1.34; 2.06) 0.48(-0.01; 0.98) 0.16(-0.58; 0.9) 0.35(-0.09; 1.35)
HJV_Eastern_EU 0.81 (0.2; 1.38) 0.5 (-0.09; 1.1) 0.1(0.02; 0.18) 0.2(0.08; 0.32) 0.1(0.02; 0.18)
HJV_Northern_EU 0.81 (0.2; 1.38) 0.3 (-0.29; 0.9) 0.1(0.02; 0.18) 0.2(0.08; 0.32) 0.1(0.02; 0.18)
HJV_Southern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.1(0.02; 0.18) 0.2(0.08; 0.32) 0.1(0.02; 0.18)
HJV_Western_EU 0.81 (0.2; 1.38) 0.7 (0.11; 1.3) 0.1(0.02; 0.18) 0.2(0.08; 0.32) 0.1(0.02; 0.18)
JEV_Eastern_EU 0.22 (-0.06; 0.46) -0.48 (-0.8; -0.2) 0.5(0.27; 0.73) 0.6(0.48; 0.72) -1.01(-1.41; 0.38)
JEV_Northern_EU 0.22 (-0.06; 0.46) -0.48 (-0.8; -0.2) 0.5(0.27; 0.73) 0.6(0.48; 0.72) -1.01(-1.41; 0.38)
JEV_Southern_EU 0.22 (-0.06; 0.46) -0.48 (-0.8; -0.2) 0.5(0.27; 0.73) 0.6(0.48; 0.72) -1.01(-1.41; 0.38)
JEV_Western_EU 0.22 (-0.06; 0.46) -0.48 (-0.8; -0.2) 0.5(0.27; 0.73) 0.8(0.68; 0.91) -0.81(-1.21; 0.38)
KASV_Eastern_EU 0.81 (0.2; 1.38) 0.61 (0; 1.21) 0.7(0.47; 0.93) 0.17(-0.6; 0.89) -0.42(-1.42; 0.56)
KASV_Northern_EU 0.81 (0.2; 1.38) 0.61 (0; 1.21) 0.7(0.47; 0.93) 0.17(-0.6; 0.89) -0.42(-1.42; 0.56)
KASV_Southern_EU 0.81 (0.2; 1.38) 0.61 (0; 1.21) 0.7(0.47; 0.93) 0.17(-0.6; 0.89) -0.42(-1.42; 0.56)
KASV_Western_EU 0.81 (0.2; 1.38) 0.61 (0; 1.21) 0.7(0.47; 0.93) 0.17(-0.6; 0.89) -0.42(-1.42; 0.56)
KOTV_Eastern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.36(-1.77; 0.37)
KOTV_Northern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.36(-1.77; 0.37)
KOTV_Southern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.36(-1.77; 0.37)
KOTV_Western_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.36(-1.77; 0.37)
MDV_Eastern_EU 0.62 (0.34; 0.86) -0.08 (-0.4; 0.2) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.94(-1.93; 0.38)
MDV_Northern_EU 0.62 (0.34; 0.86) 0.12 (-0.2; 0.4) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.74(-1.73; 0.38)
MDV_Southern_EU 0.62 (0.34; 0.86) -0.08 (-0.4; 0.2) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.94(-1.93; 0.38)
MDV_Western_EU 0.62 (0.34; 0.86) 0.32 (0; 0.6) 0.5(0.27; 0.73) 0.17(-0.6; 0.89) -0.54(-1.53; 0.38)
MIDV_Eastern_EU 0.8 (0.22; 1.37) 0.1 (-0.49; 0.7) -6(-6; -6) 0.16(-0.58; 0.9) -6(-6; -6)
MIDV_Northern_EU 0.8 (0.22; 1.37) 0.1 (-0.49; 0.7) -6(-6; -6) 0.16(-0.58; 0.9) -6(-6; -6)
MIDV_Southern_EU 0.8 (0.22; 1.37) 0.1 (-0.49; 0.7) -6(-6; -6) 0.16(-0.58; 0.9) -6(-6; -6)
MIDV_Western_EU 0.8 (0.22; 1.37) 0.1 (-0.49; 0.7) -6(-6; -6) 0.16(-0.58; 0.9) -6(-6; -6)
NSD_Eastern_EU 0.61 (-0.07; 1.25) -0.09 (-0.74; 0.56) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
NSD_Northern_EU 0.61 (-0.07; 1.25) -0.09 (-0.74; 0.56) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
NSD_Southern_EU 0.61 (-0.07; 1.25) -0.09 (-0.74; 0.56) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.51(-2.04; 0.37)
NSD_Western_EU 0.61 (-0.07; 1.25) -0.09 (-0.74; 0.56) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
PHSV_Eastern_EU 0.81 (0.2; 1.38) 0.28 (-0.69; 1.19) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.03(-1.79; 0.4)
PHSV_Northern_EU 0.81 (0.2; 1.38) 0.48 (-0.49; 1.39) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.03(-1.59; 0.56)
Vector-borne diseases
www.efsa.europa.eu/efsajournal 78 EFSA Journal 2017;15(5):4793
PHSV_Southern_EU 0.81 (0.2; 1.38) 0.28 (-0.69; 1.19) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) -0.03(-1.79; 0.4)
PHSV_Western_EU 0.81 (0.2; 1.38) 0.48 (-0.49; 1.39) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.03(-1.59; 0.56)
RFV_Eastern_EU 0.1 (-0.05; 0.25) -0.6 (-0.79; -0.4) 0.5(0.27; 0.73) 0.8(0.68; 0.91) -0.95(-1.21; 0.38)
RFV_Northern_EU 0.1 (-0.05; 0.25) -0.6 (-0.79; -0.4) 0.5(0.27; 0.73) 0.8(0.68; 0.91) -0.95(-1.21; 0.38)
RFV_Southern_EU 0.1 (-0.05; 0.25) -0.6 (-0.79; -0.4) 0.5(0.42; 0.58) 0.8(0.68; 0.91) -1(-1.22; -0.76)
RFV_Western_EU 0.1 (-0.05; 0.25) -0.6 (-0.79; -0.4) 0.5(0.27; 0.73) 0.8(0.68; 0.91) -0.95(-1.21; 0.38)
SBV_Eastern_EU 0.82 (0.54; 1.06) 0.92 (0.6; 1.2) 0.5(0.27; 0.73) 0.8(0.68; 0.91) 0.44(0.19; 0.82)
SBV_Northern_EU 0.82 (0.54; 1.06) 0.92 (0.6; 1.2) 0.47(0.23; 0.73) 0.8(0.68; 0.91) 0.41(0.18; 0.82)
SBV_Southern_EU 0.82 (0.54; 1.06) 1.12 (0.8; 1.4) 0.47(0.23; 0.73) 0.8(0.68; 0.91) 0.61(0.23; 1.02)
SBV_Western_EU 0.82 (0.54; 1.06) 1.12 (0.8; 1.4) 0.5(0.27; 0.73) 0.8(0.68; 0.91) 0.64(0.27; 1.02)
SHU_Eastern_EU 0.8 (0.22; 1.37) 0.1 (-0.49; 0.7) 0.16(0.03; 0.35) -0.6(-0.71; -0.49) 0.16(0.03; 0.35)
SHU_Northern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) -6(-6; -6) -0.6(-0.72; -0.48) -6(-6; -6)
SHU_Southern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.16(0.03; 0.34) -0.2(-0.32; -0.08) 0.16(0.03; 0.34)
SHU_Western_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) 0.16(0.03; 0.34) -0.6(-0.72; -0.48) 0.16(0.03; 0.34)
SLEV_Eastern_EU 0.61 (0.23; 0.96) 0.48 (-0.36; 1.24) 0.5(0.03; 0.97) 0.2(0.08; 0.32) -0.02(-1.29; 0.38)
SLEV_Northern_EU 0.61 (0.23; 0.96) 0.48 (-0.36; 1.24) 0.5(0.03; 0.97) 0.2(0.08; 0.32) -0.02(-1.29; 0.38)
SLEV_Southern_EU 0.61 (0.23; 0.96) 0.48 (-0.36; 1.24) 0.5(0.03; 0.97) 0.2(0.08; 0.32) -0.02(-1.29; 0.38)
SLEV_Western_EU 0.61 (0.23; 0.96) 0.68 (-0.16; 1.44) 0.5(0.03; 0.97) 0.2(0.08; 0.32) 0.04(-1.09; 0.41)
THOV_Eastern_EU 0.81 (0.2; 1.38) 1.01 (0.03; 1.93) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.14(-1.08; 1.12)
THOV_Northern_EU 0.81 (0.2; 1.38) 0.88 (-0.09; 1.79) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.1(-1.19; 0.96)
THOV_Southern_EU 0.81 (0.2; 1.38) 1.08 (0.11; 1.99) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.15(-0.99; 1.16)
THOV_Western_EU 0.81 (0.2; 1.38) 1.08 (0.11; 1.99) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
VEE_Eastern_EU 0.4 (0.13; 0.67) 0.4 (0.11; 0.68) 0.15(0.03; 0.34) -0.4(-0.52; -0.29) 0.15(0.03; 0.34)
VEE_Northern_EU 0.4 (0.13; 0.67) 0.8 (0.51; 1.08) -6(-6; -6) -0.6(-0.72; -0.49) -6(-6; -6)
VEE_Southern_EU 0.4 (0.13; 0.67) 0.4 (0.11; 0.68) 0.15(0.03; 0.34) 0(-0.12; 0.11) 0.15(0.03; 0.34)
VEE_Western_EU 0.4 (0.13; 0.67) 1 (0.71; 1.28) 0.15(0.03; 0.34) 0(-0.12; 0.11) 0.15(0.03; 0.34)
VSV_Eastern_EU 0.72 (0.19; 1.19) 0.51 (0; 1.02) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0(-1.35; 0.4)
VSV_Northern_EU 0.72 (0.19; 1.19) 0.71 (0.2; 1.22) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.05(-1.15; 0.59)
VSV_Southern_EU 0.72 (0.19; 1.19) 0.5 (-0.15; 1.17) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.01(-1.39; 0.4)
VSV_Western_EU 0.72 (0.19; 1.19) 0.71 (0.2; 1.22) 0.5(0.03; 0.97) 0.17(-0.6; 0.89) 0.05(-1.15; 0.59)
WEEV_Eastern_EU 0.61 (-0.07; 1.25) 0.31 (-0.34; 0.96) 0.16(0.03; 0.34) 0.8(0.68; 0.91) 0.16(0.03; 0.34)
WEEV_Northern_EU 0.61 (-0.07; 1.25) 0.11 (-0.54; 0.76) 0.16(0.03; 0.34) 0.8(0.68; 0.91) 0.16(0.03; 0.34)
WEEV_Southern_EU 0.61 (-0.07; 1.25) 0.11 (-0.54; 0.76) 0.16(0.03; 0.34) 0.8(0.68; 0.91) 0.16(0.03; 0.34)
WEEV_Western_EU 0.61 (-0.07; 1.25) 0.51 (-0.14; 1.16) 0.16(0.03; 0.34) 0.8(0.68; 0.91) 0.16(0.03; 0.34)
WNV_Eastern_EU 0.21 (-0.04; 0.43) 0.9 (0.65; 1.14) 0.5(0.27; 0.73) 0.8(0.68; 0.91) 0.45(0.23; 0.76)
WNV_Northern_EU 0.21 (-0.04; 0.43) 0.9 (0.65; 1.14) 0.5(0.27; 0.73) 0.8(0.68; 0.91) 0.45(0.23; 0.76)
WNV_Southern_EU 0.21 (-0.04; 0.43) 0.9 (0.65; 1.14) 0.5(0.27; 0.73) 0.89(0.81; 0.97) 0.55(0.26; 0.83)
WNV_Western_EU 0.21 (-0.04; 0.43) 0.9 (0.65; 1.14) 0.47(0.23; 0.73) 0.89(0.81; 0.97) 0.52(0.23; 0.82)
WSLV_Eastern_EU 0.79 (0.21; 1.39) 0.09 (-0.51; 0.72) -6(-6; -6) 0.16(-0.61; 0.89) -6(-6; -6)
WSLV_Northern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
WSLV_Southern_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
WSLV_Western_EU 0.81 (0.2; 1.38) 0.1 (-0.49; 0.7) -6(-6; -6) 0.17(-0.6; 0.89) -6(-6; -6)
YUOV_Eastern_EU 0.81 (0.2; 1.38) 0.28 (-0.69; 1.19) 0.5(0.03; 0.97) -0.6(-0.72; -0.48) -0.98(-2.34; 0.37)
YUOV_Northern_EU 0.81 (0.2; 1.38) 0.48 (-0.49; 1.39) -6(-6; -6) -0.6(-0.72; -0.48) -6(-6; -6)
YUOV_Southern_EU 0.8 (0.22; 1.37) 0.25 (-0.68; 1.23) 0.5(0.03; 0.98) 0.2(0.09; 0.31) -0.29(-1.58; 0.37)
YUOV_Western_EU 0.82 (0.21; 1.39) 0.5 (-0.55; 1.37) -6(-6; -6) -0.6(-0.72; -0.49) -6(-6; -6)
very high high/very high high moderate/high moderate
low/moderate low very low/low very low
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Table D.2: Model outputs for the steps post-introduction
Area potentially at risk Annual extent
of spread
Overwintering Estimated
epidemic size
Production losses Impact on 
animal welfare
AHFV_Eastern_EU
AHFV_Northern_EU
AHFV_Southern_EU
AHFV_Western_EU
AHSV_Eastern_EU
AHSV_Northern_EU
AHSV_Southern_EU
AHSV_Western_EU
AINOV_Eastern_EU
AINOV_Northern_EU
AINOV_Southern_EU
AINOV_Western_EU
AKAV_Eastern_EU
AKAV_Northern_EU
AKAV_Southern_EU
AKAV_Western_EU
ASFV_Eastern_EU
ASFV_Northern_EU
ASFV_Southern_EU
ASFV_Western_EU
BEFV_Eastern_EU
BEFV_Northern_EU
BEFV_Southern_EU
BEFV_Western_EU
BHAV_Eastern_EU
BHAV_Northern_EU
BHAV_Southern_EU
BHAV_Western_EU
BTV_Eastern_EU 0.56(0.11; 1.64) 0.5(0.42; 0.58) 0.37(-0.14; 1.79) 0.18(-0.13; 0.88) 0.18(-0.2; 0.9)
BTV_Northern_EU 0.55(0.17; 1.24) 0.5(0.42; 0.58) 0.36(-0.09; 1.26) 0.18(-0.08; 0.64) 0.17(-0.2; 0.9)
BTV_Southern_EU 0.65(0.18; 1.57) 0.53(0.46; 0.59) 0.46(-0.09; 1.72) 0.25(-0.08; 0.86) 0.24(-0.14; 0.87)
BTV_Western_EU 0.65(0.25; 1.28) 0.5(0.42; 0.58) 0.46(0; 1.26) 0.24(-0.04; 0.66) 0.24(-0.09; 0.68)
CanL_Eastern_EU 0.1(0.03; 0.21) 0.7(0.51; 0.93) -0.03(-0.16; 0.23) -0.42(-0.49; -0.34) 0.05(-0.05; 0.14)
CanL_Eastern_EU 0.1(0.03; 0.21) 0.7(0.51; 0.93) -0.03(-0.16; 0.23) -0.42(-0.49; -0.34) 0.05(-0.05; 0.14)
CanL_Northern_EU 0(0; 0) 0.5(0.42; 0.58) -0.19(-0.2; -0.18) -0.53(-0.53; -0.52) -0.07(-0.12; -0.01)
CanL_Southern_EU 0.09(0.07; 0.14) 0.7(0.51; 0.93) -0.04(-0.13; 0.11) -0.43(-0.47; -0.37) 0.04(-0.04; 0.12)
CanL_Western_EU 0.1(0.03; 0.21) 0.7(0.51; 0.93) -0.03(-0.16; 0.23) -0.42(-0.49; -0.34) 0.05(-0.05; 0.14)
CCHFV_Eastern_EU 0.09 (0.03; 0.27) 0.93(0.86; 0.99) -0.05(-0.08; 0.3) -0.39(-0.43; -0.26) -0.05(-0.21; 0.13)
CCHFV_Northern_EU 0.1(0.03; 0.28) 0.93(0.86; 0.99) 0.02(-0.05; 0.3) -0.39(-0.43; -0.26) -0.05(-0.21; 0.13)
CCHFV_Southern_EU 0.1(0.07; 0.21) 0.93(0.86; 0.99) 0.02(-0.02; 0.16) -0.39(-0.41; -0.32) -0.05(-0.2; 0.12)
CCHFV_Western_EU 0.1(0.03; 0.28) 0.93(0.86; 0.99) 0.02(-0.05; 0.3) -0.39(-0.43; -0.26) -0.05(-0.12; 0.08)
Cowdr_Eastern_EU
Cowdr_Northern_EU
Cowdr_Southern_EU
Cowdr_Western_EU
CVV_Eastern_EU 0.07(0.01; 0.8) 0.5(0.12; 0.97) -0.06(-0.19; 0.96) -0.09(-0.51; 0.43) -0.05(-0.45; 0.46)
CVV_Northern_EU 0.07(0.01; 0.47) 0.5(0.12; 0.97) -0.07(-0.19; 0.5) -0.12(-0.51; 0.29) -0.07(-0.45; 0.3)
CVV_Southern_EU 0.07(0.01; 1.43) 0.56(0.43; 0.97) -0.06(-0.19; 1.77) -0.07(-0.51; 0.83) -0.03(-0.45; 0.85)
CVV_Western_EU 0.07(0.01; 1.08) 0.5(0.12; 0.97) -0.06(-0.19; 0.96) -0.09(-0.51; 0.43) -0.05(-0.45; 0.46)
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EEEV_Eastern_EU 0.07(0.01; 1.08) 0.15(0.09; 0.19) -0.2(-0.2; -0.2) -0.22(-0.53; 0.11) -0.07(-0.23; 0.09)
EEEV_Northern_EU 0.07(0.01; 0.51) 0.15(0.09; 0.19) -0.13(-0.19; 0.49) -0.14(-0.52; 0.3) 0(-0.18; 0.29)
EEEV_Southern_EU 0.07(0.01; 1.35) 0.5(0.42; 0.58) -0.12(-0.19; 1.72) -0.1(-0.51; 0.76) 0.01(-0.18; 0.84)
EEEV_Western_EU 0.07(0.01; 0.77) 0.15(0.09; 0.19) -0.13(-0.19; 0.87) -0.12(-0.52; 0.42) 0(-0.18; 0.47)
EEV_Eastern_EU
EEV_Northern_EU
EEV_Southern_EU
EEV_Western_EU
EHD_Eastern_EU
EHD_Northern_EU
EHD_Southern_EU
EHD_Western_EU
GETV_Eastern_EU
GETV_Northern_EU
GETV_Southern_EU
GETV_Western_EU
Hepatozoon_Eastern_EU 0.14(0.01; 0.58) 0.72(0.66; 0.78) 0.01(-0.15; 0.49) -0.39(-0.49; -0.11) 0.11(-0.13; 0.42)
Hepatozoon_Northern_EU 0.14(0.01; 0.58) 0.72(0.66; 0.78) 0.01(-0.15; 0.49) -0.39(-0.49; -0.11) 0.11(-0.13; 0.42)
Hepatozoon_Southern 0.16(0.01; 0.58) 0.72(0.66; 0.78) 0.03(-0.15; 0.5) -0.38(-0.49; -0.1) 0.09(-0.05; 0.38)
Hepatozoon_Western 0.16(0.01; 0.58) 0.72(0.66; 0.78) 0.03(-0.15; 0.5) -0.38(-0.49; -0.1) 0.11(-0.13; 0.43)
HJV_Eastern_EU
HJV_Northern_EU
HJV_Southern_EU
HJV_Western_EU
JEV_Eastern_EU
JEV_Northern_EU
JEV_Southern_EU
JEV_Western_EU
KASV_Eastern_EU
KASV_Northern_EU
KASV_Southern_EU
KASV_Western_EU
KOTV_Eastern_EU
KOTV_Northern_EU
KOTV_Southern_EU
KOTV_Western_EU
MDV_Eastern_EU
MDV_Northern_EU
MDV_Southern_EU
MDV_Western_EU
MIDV_Eastern_EU
MIDV_Northern_EU
MIDV_Southern_EU
MIDV_Western_EU
NSD_Eastern_EU
NSD_Northern_EU
NSD_Southern_EU
NSD_Western_EU
PHSV_Eastern_EU
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PHSV_Northern_EU
PHSV_Southern_EU
PHSV_Western_EU
RFV_Eastern_EU
RFV_Northern_EU
RFV_Southern_EU
RFV_Western_EU
SBV_Eastern_EU 0.84(0.05; 2.63) 0.5(0.42; 0.58) 0.65(-0.16; 2.94) 0.36(-0.18; 1.52) 0.15(-0.42; 1.33)
SBV_Northern_EU 0.41(0.04; 1.34) 0.5(0.42; 0.58) 0.22(-0.18; 1.38) 0.08(-0.19; 0.7) -0.14(-0.45; 0.46)
SBV_Southern_EU 1.1(0.04; 4.04) 0.52(0.46; 0.58) 0.9(-0.18; 4.7) 0.53(-0.19; 2.5) 0.33(-0.44; 2.3)
SBV_Western_EU 1.14(0.05; 3.57) 0.5(0.42; 0.58) 0.95(-0.16; 4.11) 0.56(-0.18; 2.18) 0.34(-0.42; 1.99)
SHU_Eastern_EU
SHU_Northern_EU
SHU_Southern_EU
SHU_Western_EU
SLEV_Eastern_EU
SLEV_Northern_EU
SLEV_Southern_EU
SLEV_Western_EU
THOV_Eastern_EU
THOV_Northern_EU
THOV_Southern_EU
THOV_Western_EU
VEE_Eastern_EU
VEE_Northern_EU
VEE_Southern_EU
VEE_Western_EU
VSV_Eastern_EU
VSV_Northern_EU
VSV_Southern_EU
VSV_Western_EU
WEEV_Eastern_EU
WEEV_Northern_EU
WEEV_Southern_EU
WEEV_Western_EU
WNV_Eastern_EU 0.6 (0.08; 1.87) 0.9(0.82; 0.98) 0.52(-0.03; 2.14) -0.05(-0.4; 0.79) 0.16(-0.27; 0.99)
WNV_Northern_EU 0.38(0.08; 1.03) 0.9(0.82; 0.98) 0.03(-0.03; 1.11) -0.2(-0.4; 0.23) 0.02(-0.28; 0.45)
WNV_Southern_EU 0.9 (0.08; 3.05) 0.9(0.82; 0.98) 0.82(-0.03; 2.97) -0.34(-0.42; 0.86) 0.35(-0.27; 1.28)
WNV_Western_EU 0.52(0.06; 1.84) 0.9(0.82; 0.98) 0.44(-0.06; 2.09) -0.11(-0.41; 0.77) 0.1 (-0.28; 0.95)
WSLV_Eastern_EU
WSLV_Northern_EU
WSLV_Southern_EU
WSLV_Western_EU
YUOV_Eastern_EU
YUOV_Northern_EU
YUOV_Southern_EU
YUOV_Western_EU
very high high/very high high moderate/high moderate
low/moderate low very low/low very low
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Appendix E – Biocidal products
According to Reg (EU) No 528/2012, concerning the making available on the market and use of
biocidal products, active substances belonging to product type 18 and 19 are taken into account in this
opinion. Product type 18 (i.e. insecticides, acaricides and products to control other arthropods) is used
for the control of arthropods (e.g. insects, arachnids and crustaceans) by means other than repulsion
or attraction. Similarly product type 19 (i.e. repellents and attractants) is applied to control harmful
organisms (invertebrates such as ﬂeas, vertebrates such as birds, ﬁsh, rodents), by repelling or
attracting, including those that are used for human or veterinary hygiene either directly on the skin or
indirectly in the environment of humans or animals.
According to Reg (EU) No 528/2012 Annex VI, the risk characterisation for the environment
considers the estimation of the incidence and severity of the adverse effects likely to occur in
environmental compartments due to actual or predicted exposure to any active substance or substance
of concern in a biocidal product. For any given environmental compartment, the risk characterisation
must, as far as possible, entail comparison of the Predicted Environmental Concentration (PEC) with
the (Predicted No Effect Concentration (PNEC) so that a PEC/PNEC ratio may be derived. If PEC/PNEC
ratio < 1, no risks are identiﬁed. If the PEC/PNEC ratio is > 1, the Competent Authority must judge, on
the basis of the size of that ratio and on other relevant factors, if further information and/or testing
are required to clarify the concern, if risk reduction measures are necessary or if the substance cannot
be included in the Union List at all. If it has not been possible to derive a PEC/PNEC ratio, the risk
characterisation must entail a qualitative evaluation of the likelihood that an effect is occurring under
the current conditions of exposure or will occur under the expected conditions of exposure. Data from
the approved active substances that are to be used for controlling the relevant vectors species were
extracted, such as information on the target species, intended uses (e.g. indoor/outdoor, professional/
non-professional use), application/dose rate (i.e. efﬁcacy), hazard class category and risk
characterisation ratios (RCRs).
Table E.1: Overview table of product type 18 and 19 for which an application for approval has
been submitted under Directive 98/8/EC (BPD) or Regulation (EU) No 528/2012 (BPR),
including ‘existing’ active substances included in the Review Programme and ‘new’ active
substances, and those already ‘approved’ and those where the application is on-going
(‘under review’). Updated version available at http://echa.europa.eu/information-on-
chemicals/biocidal-active-substances
Product type Approved a.s. Under review a.s. Not approved a.s. TOT
PT_18 34 27 1 62
PT_19 8 8 – 16
Vector-borne diseases
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